-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, BmzrEonKSNqPoMSOc+/ub4eONuNmQzCbJ5srb32hSXkGm88Jd9H7VodmLnAbgHU/ ZVu3dvtxJLwlfxzZLwaIyw== 0000936392-97-001122.txt : 19970815 0000936392-97-001122.hdr.sgml : 19970815 ACCESSION NUMBER: 0000936392-97-001122 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 19970630 FILED AS OF DATE: 19970814 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 97661932 BUSINESS ADDRESS: STREET 1: 3050 SCIENCE PARK RD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6196587600 MAIL ADDRESS: STREET 1: 3050 SCIENCE PARK ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 10-Q 1 FORM 10-Q 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITES AND EXCHANGE ACT OF 1934 For the quarterly period ended JUNE 30, 1997 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from ______________________ to ____________________ Commission file number 0-28150 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) DELAWARE 33-0525145 (State or other jurisdiction of (IRS Employer Identification No.) incorporation or organization) 3050 SCIENCE PARK ROAD SAN DIEGO, CALIFORNIA 92121 (Address of principal executive offices) (619) 658-7600 (Registrant's telephone number, including area code) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes X No ----- ----- The number of outstanding shares of the registrant's Common Stock, no par value, was 16,949,772 as of July 31, 1997 2 NEUROCRINE BIOSCIENCES, INC FORM 10-Q INDEX
PAGE ---- PART I FINANCIAL INFORMATION ITEM 1: Financial Statements............................................................................... 3 Condensed Balance Sheets as of June 30, 1997 and December 31, 1996................................. 3 Condensed Statements of Operations for the three months and six months ended June 30, 1997 and 1996....................................................................... 4 Condensed Statements of Cash Flows for the six months ended June 30, 1997 and 1996....................................................................... 5 Notes to Financial Statements...................................................................... 6 ITEM 2: Management's Discussion and Analysis of Financial Condition and Results of Operations.......................................................................... 7 Overview........................................................................................... 7 Results of Operations.............................................................................. 7 Liquidity and Capital Resources.................................................................... 8 PART II OTHER INFORMATION.................................................................................. 10 ITEM 4. Submission of Matters to a Vote of Security Holders................................................ 10 ITEM 6: Exhibits........................................................................................... 12 10.1 Employment agreement executed March 1, 1997 between the Registrant and Gary A. Lyons. 10.2 Employment agreement executed March 1, 1997 between the Registrant and Errol B. DeSouza. 10.3 Employment agreement executed March 1, 1997 between the Registrant and Paul W. Hawran. 27.1 Financial Data Schedule. SIGNATURES ................................................................................................... 13
2 3 PART I. FINANCIAL INFORMATION Item 1. FINANCIAL STATEMENTS NEUROCRINE BIOSCIENCES, INC. CONDENSED BALANCE SHEETS
JUNE 30, DECEMBER 31, 1997 1996 ------------ ------------ (UNAUDITED) (NOTE) ASSETS Current assets: Cash and cash equivalents $ 22,945,469 $ 11,325,361 Short-term investments, available for sale 40,631,271 58,594,853 Receivables under collaborative agreements 7,653,719 1,329,513 Other current assets 1,327,645 840,962 ------------ ------------ Total current assets 72,558,104 72,090,689 Property, equipment, and leasehold improvements, net 5,516,054 3,546,420 Licensed technology and patent application costs, net 1,352,265 1,443,403 Other assets 4,594,102 876,070 ------------ ------------ Total assets $ 84,020,525 $ 77,956,582 ============ ============ LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 526,891 $ 800,157 Accrued expenses, other current liabilities, and current portion of obligations under capital leases 4,969,128 3,267,357 ------------ ------------ Total current liabilities 5,496,019 4,067,514 Long-term liabilities 1,150,187 1,122,100 Stockholders' equity: Preferred Stock, $0.001 par value, 5,000,000 shares authorized, no shares issued and outstanding Common stock, no par value: Authorized shares - 100,000,000 Issued and outstanding shares - 16,938,569 shares in 1997 16,776,614 in 1996 83,151,069 82,788,513 Accumulated deficit (5,776,750) (10,021,545) ------------ ------------ Total stockholders' equity 77,374,319 72,766,968 ------------ ------------ Total liabilities and stockholders' equity $ 84,020,525 $ 77,956,582 ============ ============
Note: The balance sheet at December 31, 1996 has been derived from the audited financial statements at that date, but does not include all of the disclosures required by generally accepted accounting principles. See accompanying notes to condensed financial statements. 3 4 NEUROCRINE BIOSCIENCES, INC. CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)
THREE MONTHS ENDED SIX MONTHS ENDED JUNE 30, JUNE 30, ------------------------------- ------------------------------- 1997 1996 1997 1996 ------------ ------------ ------------ ------------ Revenues under collaborative research agreements: Sponsored research $ 2,637,500 $ 1,625,000 $ 5,275,000 $ 3,250,000 Milestones 1,000,000 3,000,000 6,000,000 3,000,000 Other revenue 1,163,694 886,416 2,380,085 1,420,394 ------------ ------------ ------------ ------------ Total revenues 4,801,194 5,511,416 13,655,085 7,670,394 Operating expenses Research and development 4,440,251 3,512,469 9,029,329 5,306,953 General and administration 1,343,901 724,387 2,488,450 1,295,184 ------------ ------------ ------------ ------------ Total operating expenses 5,784,152 4,236,856 11,517,779 6,602,137 ------------ ------------ ------------ ------------ Income (loss) from operations (982,958) 1,274,560 2,137,306 1,068,257 Interest income 910,037 489,051 1,833,268 748,215 Interest expense (40,785) (66,117) (88,411) (137,939) Other income 239,512 59,954 439,025 103,581 ------------ ------------ ------------ ------------ Income before income taxes 125,806 1,757,448 4,321,188 1,782,114 Provision for income taxes 22,393 -- 76,393 -- ------------ ------------ ------------ ------------ Net income $ 103,413 $ 1,757,448 $ 4,244,795 $ 1,782,114 ============ ============ ============ ============ Net income per share $ 0.01 $ 0.11 $ 0.23 $ 0.12 ============ ============ ============ ============ Shares used in computing net income per share 18,197,434 15,412,571 18,149,386 14,422,918 ============ ============ ============ ============
See accompanying notes to condensed financial statements. 4 5 NEUROCRINE BIOSCIENCES, INC. CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)
SIX MONTHS ENDED JUNE 30, ------------------------------- 1997 1996 ------------ ------------ OPERATING ACTIVITIES Net income $ 4,244,795 $ 1,782,114 Adjustments to reconcile net income to cash used in operating activities: Compensation expense recognized for stock options 71,216 27,989 Depreciation and amortization 559,185 433,491 Deferred revenue 1,750,000 326,616 Deferred rent 201,423 27,638 Change in operating assets and liabilities: Other current assets (6,810,888) (5,132,770) Other assets (3,718,032) (218,653) Accounts payable and accrued liabilities (83,934) 100,520 ------------ ------------ Net cash flows used in operating activities (3,786,235) (2,653,055) INVESTING ACTIVITIES Purchases of short-term investments (38,986,324) (51,111,011) Sales/maturities of short-term investments 56,870,228 22,955,598 Purchase of licensed technology and expenditures for patent application costs -- (405,296) Purchases of furniture, equipment and leasehold improvements (2,437,681) (677,013) ------------ ------------ Net cash flows provided by (used in) investing activities 15,446,223 (29,237,722) FINANCING ACTIVITIES Issuance of common stock, net 365,781 47,507,488 Principal payments on obligations under capital leases (410,898) (359,949) Payments received on notes receivable from stockholders 5,237 5,237 ------------ ------------ Net cash flows (used in) provided by financing activities (39,880) 47,152,776 ------------ ------------ Increase in cash and cash equivalents 11,620,108 15,261,999 Cash and cash equivalents at beginning of period 11,325,361 6,392,749 ------------ ------------ Cash and cash equivalents at end of period $ 22,945,469 $ 21,654,748 ============ ============ SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Interest paid $ 88,411 $ 71,836 ============ ============ Taxes paid $ 135,000 $ -- ============ ============
See accompanying notes to condensed financial statements. 5 6 NEUROCRINE BIOSCIENCES, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS 1. BASIS OF PRESENTATION The interim unaudited condensed financial statements contained herein have been prepared in accordance with generally accepted accounting principles for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The financial statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of the financial position, results of operations, and cash flows for the periods presented. The results of operations for the interim periods shown in this report are not necessarily indicative of results expected for the full year. The financial statements should be read in conjunction with the audited financial statements and notes for the year ended December 31, 1996, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission. 2. NET INCOME PER SHARE Net income per share is computed using the weighted average number of shares of common stock outstanding during each period. Common stock equivalent shares from stock options, warrants, and convertible preferred shares are excluded from the computation when their effect is antidilutive. For the three and six month periods ended June 30, 1997 and 1996, shares used in computing net income per share also include common equivalent shares arising from dilutive stock options, warrants, and convertible preferred shares using the treasury stock method. Income per share on a fully diluted basis was unchanged. In February 1997, the Financial Accounting Standards Board issued Statement No. 128, "Earnings per Share," which is required to be adopted on December 31, 1997. At that time, the Company will be required to change the method currently used to compute earnings per share and to restate all prior periods. Under the new method, the dilutive effect of common stock equivalents will be excluded from "basic" earnings per share, and basic earnings per share for the three and six months ended June 30, 1997 and 1996 will be $0.01 and $0.25, respectively. Under the new method, "diluted" earnings per share will not be materially different than earnings per share as presented herein. 3. SUBSEQUENT EVENT In May 1997 the Company purchased two adjacent parcels of land in San Diego for approximately $5.0 million in cash. In August 1997 the Company sold one parcel of land for the purpose of constructing an expanded laboratory and office complex which it then intends to lease under a 15 year operating lease. The land purchase price of approximately $3.5 million plus a future cash payment of $355,000 will be repaid to the Company under a 10 year promissory note bearing interest at 8.25% per annum. The Company has an option to purchase the facility at any time during the lease at a predetermined price. 6 7 ITEM 2. MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following Management's Discussion and Analysis of Financial Condition and Results of Operations of Neurocrine Biosciences, Inc. ("Neurocrine" or the "Company") contain forward-looking statements which involve risks and uncertainties, pertaining generally to the expected continuation of the Company's collaborative agreements, the receipt of research payments thereunder, the future achievement of various milestones in product development and the receipt of payments related thereto, the potential receipt of royalty payments, the period of time the Company's existing capital resources will meet its funding requirements, and financial results and operations. Actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below and those outlined in the Company's 1996 Annual Report on Form 10-K filed with the Securities and Exchange Commission. OVERVIEW Since the founding of the Company in January 1992, Neurocrine has been engaged in the discovery and development of novel pharmaceutical products for diseases and disorders of the central nervous and immune systems. To date, Neurocrine has not generated any revenues from the sale of products, and does not expect to generate any product revenues for the foreseeable future. The Company's revenues are expected to come from its strategic alliances. The Company has generated net income for the three and six month periods ended June 30, 1996 and 1995 primarily from revenues from its strategic alliances. The Company does not anticipate continuing to generate net income as its operating expenses are anticipated to rise significantly in future periods as products are advanced through the various stages of clinical development. Neurocrine has incurred a cumulative deficit of approximately $5.8 million as of June 30, 1997 and expects to incur operating losses in the future which are potentially greater than losses in prior years. RESULTS OF OPERATIONS Three Months Ended June 30, 1997 Compared to Three Months Ended June 30, 1996 Revenues decreased to $4.8 million for the quarter ended June 30, 1997 compared with $5.5 million for the same period in 1996. Decreased revenues were primarily the result of timing of research milestone payments received under the Company's corporate collaborations. Research and development expenses increased to $4.4 million for the quarter ended June 30, 1997 compared with $3.5 million for the same period in 1996. This increase reflected continued additions to scientific and clinical development personnel, and related support expenditures, as the Company increased its research and clinical development activities. Clinical development costs include significant amounts which are reimbursable under corporate collaborations. Revenues associated with such reimbursements are classified as "Other revenue". General and administrative expenses increased to $1.3 million for the quarter ended June 30, 1997 compared with $724,000 for the same period in 1996. This increase resulted from additional administrative personnel and related business development and professional services expenses to support the increased research and development efforts and higher patent application costs. Interest income increased to $910,000 for the quarter ended June 30, 1997 compared with $489,000 for the same period in 1996. This increase was due to increased investment income attributable to increased cash equivalents and short term investments. Net income decreased to $103,000 or $0.01 per share for the quarter ended June 30, 1997 compared with $1.8 million or $0.11 per share for the same period in 1996. The decrease in net income and net income per share was primarily attributable to a decrease in research milestone revenues and increased operating expenses. The Company's revenues to date have come from funded research and achievement of milestones under corporate collaborations which leads to substantial fluctuations in the results of quarterly revenues and earnings. Accordingly, results of one quarter are not predictive of future quarters. 7 8 MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Six Months Ended June 30, 1997 Compared to Six Months Ended June 30, 1996 Revenues increased to $13.7 million for the six month period ended June 30, 1997 compared with $7.7 million for the same period in 1996. The increase was primarily due to achievement of a research milestone and sponsored research revenues recognized under the collaboration with Eli Lilly. Research and development expenses increased to $9.0 million for the six month period ended June 30, 1997 compared with $5.3 million for the same period in 1996. This increase reflected continued additions to scientific and clinical development personnel, and related support expenditures, as the Company increased its research and clinical development activities. Clinical development costs include significant amounts which are reimbursable under corporate collaborations. Revenues associated with such reimbursements are classified as "Other revenue". General and administrative expenses increased to $2.5 million for the six month period ended June 30, 1997 compared with $1.3 million for the same period in 1996. This increase resulted from additional administrative personnel and related business development and professional services expenses to support the increased research and development efforts and higher patent application costs. Interest income increased to $1.8 million for the six month period ended June 30, 1997 compared with $748,000 for the same period in 1996. This increase was due to increased investment income attributable to increased cash equivalents and short term investments. Net income increased to $4.2 million or $0.23 per share for the six month period ended June 30, 1997 compared with $1.8 million or $0.12 per share for the same period in 1996. The increase in net income and net income per share was primarily due to achievement of a research milestone, and sponsored research revenues recognized under the collaboration with Eli Lilly. The Company's revenues to date have come from funded research and achievement of milestones under corporate collaborations which leads to substantial fluctuations in the results of year-to-date revenues and earnings. Accordingly, results of one period are not predictive of future periods. LIQUIDITY AND CAPITAL RESOURCES At June 30, 1997 the Company's cash, cash equivalents, and short-term investments totaled $63.6 million. Cash held by the Company excludes $7.7 million due from corporate collaborators of which $4.7 million had been collected as of July 31, 1997. Total cash, cash equivalents, and short-term investments also excludes approximately $7.5 million held by Neuroscience Pharma (NPI) Inc. which is available to fund certain of the Company's research and development activities. Cash used in operating activities during the six month period ended June 30, 1997 increased to $3.8 million compared with $2.7 million for the same period in 1996. The increase was primarily the result of increased operating expenses and the timing of receipt of receivables due from corporate collaborators. Cash provided by investing activities during the six month period ended June 30, 1997 increased to $15.4 million compared with a net use of $29.2 million for the same period in 1996. The increase was primarily the result of timing differences in investment purchases and sales/maturities and fluctuations in the Company's portfolio mix between cash equivalent and short-term investment holdings. Cash used in financing activities during the six month period ended June 30, 1997 increased to $40,000 compared with a net provision of $47.1 million for the same period in 1996. The increase was due to a decline in cash generated from equity offerings from the same period in 1996. 8 9 MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Neurocrine has primarily financed its operations through proceeds of approximately $63.6 million from the sale of Common Stock in various private and public offerings and approximately $48.4 million from corporate collaborations. In May 1997 the Company purchased two adjacent parcels of land in San Diego for approximately $5.0 million in cash. In August 1997 the Company sold one parcel of land for the purpose of constructing an expanded laboratory and office complex which it then intends to lease under a 15 year operating lease. The land purchase price of approximately $3.5 million plus a future cash payment of $355,000 will be repaid to the Company under a 10 year promissory note bearing interest at 8.25% per annum. The Company has an option to purchase the facility at any time during the lease at a predetermined price. The remaining parcel will be held by the Company until such time as the Company's growth requires additional expansion. The Company believes that its existing capital resources, together with interest income and future payments due under the strategic alliances, will be sufficient to satisfy its current and projected funding requirements at least through 2000. However, no assurance can be given that such capital resources and payments will be sufficient to conduct its research and development programs as planned. The amount and timing of expenditures will vary depending upon a number of factors, including progress of the Company's research and development programs. The Company's business is subject to significant risks, including but not limited to, the risks inherent in its research and development activities, including the successful continuation of the Company's strategic collaborations, the successful completion of clinical trials, the lengthy, expensive and uncertain process of seeking regulatory approvals, uncertainties associated both with obtaining and enforcing its patents and with patent rights of others, uncertainties regarding government reforms and of product pricing and reimbursement levels, technological change and competition, manufacturing uncertainties and dependence on third parties. Even if the Company's product candidates appear promising at an early stage of development, they may not reach the market for numerous reasons. Such reasons include the possibilities that the product will be ineffective or unsafe during clinical trials, will fail to receive necessary regulatory approvals, will be difficult to manufacture on large scale, will be uneconomical to market or will be precluded from commercialization by proprietary rights of third parties. Neurocrine will require additional funding for the continuation of its research and product development programs, for progress with preclinical testing and clinical trials, for operating expenses, for the pursuit of regulatory approvals for its product candidates, for the costs involved in filing and prosecuting patent applications and enforcing patent claims, if any, the cost of product in-licensing and any possible acquisitions, and may require additional funding for establishing manufacturing and marketing capabilities in the future. The Company may seek to access the public or private equity markets whenever conditions are favorable. The Company may also seek additional funding through strategic alliances and other financing mechanisms, potentially including off-balance sheet financing. There can be no assurance that adequate funding will be available on terms acceptable to the Company, if at all. If adequate funds are not available, the Company may be required to curtail significantly one or more of its research or development programs or obtain funds through arrangements with collaborative partners or others. This may require the Company to relinquish rights to certain of its technologies or product candidates. The Company has generated net income for the three and six month periods ended June 30, 1996 and 1995 primarily from revenues from its strategic alliances. Continued profitability is not expected as the Company's operating expenses are anticipated to rise significantly in future periods as products are advanced through the various development stages. Neurocrine expects to incur additional operating expenses over the next several years as its research, development, preclinical testing and clinical trial activities increase. To the extent that the Company is unable to obtain third party funding for such expenses, the Company expects that increased expenses will result in increased losses from operations. There can be no assurance that the Company's products under development will be successfully developed or that its products, if successfully developed, will generate revenues sufficient to enable the Company to earn a profit. 9 10 PART II - OTHER INFORMATION ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS (a) The Annual Meeting of Stockholders of Neurocrine Biosciences, Inc. was held on May 27, 1997. (b) The following Class I Directors were elected to serve for a term of three years to expire at the Company's 2000 Annual Meeting of Stockholders: Name Position Term Expires --------------------- ----------------------------- ------------ Wylie W. Vale Class I Director 2000 Joseph A. Mollica Class I Director 2000 Errol B. DeSouza Class I Director 2000 The following Class II and III Directors continue to serve their respective terms which expire on the Company's Annual Meeting of Stockholders in the year as noted: Name Position Term Expires --------------------- ----------------------------- ------------ Howard Birndorf Class II Director 1998 David Robinson Class II Director 1998 Gary Lyons Class III Director 1999 Harry Hixson Class III Director 1999 (c) The matters voted upon at the meeting and the voting results were as follows: (i) Approval of amendment to the Company's Bylaws increasing the number of directors on the Board of Directors from six to seven: For Against Abstain -------------- ----------- ---------- 10,772,021 125,617 7,000 (ii) The election of three Class I Directors for a term of three years: Name For Against Abstain --------------------- -------------- ----------- ---------- Wylie W. Vale 10,834,170 156,502 -- Joseph A. Mollica 10,834,170 156,502 -- Errol B. DeSouza 10,834,170 156,502 -- (iii) Approval of amendment to the Company's 1992 Incentive Stock Plan, increasing the number of shares of Common Stock reserved for issuance from 3,300,000 to 4,100,000 Shares: For Against Abstain -------------- ----------- ---------- 10,281,373 600,067 231,198 (iv) Ratification of the appointment of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 1997: For Against Abstain -------------- ----------- ---------- 10,972,177 9,565 8,930 ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K a. Exhibits. The following exhibits are filed as part of, or incorporated by reference into, this report:
Exhibit Number Description ------ ----------- 10.1 Employment agreement executed March 1, 1997 between the Registrant and Gary A. Lyons. 10.2 Employment agreement executed March 1, 1997 between the Registrant and Errol B. DeSouza. 10.3 Employment agreement executed March 1, 1997 between the Registrant and Paul W. Hawran. 27.4 Financial Data Schedule
b. Reports on Form 8-K. No reports on Form 8-K were filed during the quarter ended June 30, 1997. 10 11 SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NEUROCRINE BIOSCIENCES, INC. Dated: 08/15/97 /s/ Paul Hawran ------------------------------------------------- PAUL W. HAWRAN Senior Vice President and Chief Financial Officer 11 EX-10.1 2 EXHIBIT 10.1 1 EXHIBIT 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AGREEMENT, dated as of March 1, 1997, is made by and between NEUROCRINE BIOSCIENCES, INC., a Delaware corporation (hereinafter the "Company"), and GARY A. LYONS (hereinafter "Executive"). RECITALS WHEREAS, the Company and Executive entered into an employment agreement as of March 1, 1993; WHEREAS, the Company and Executive wish to set forth in this Agreement the terms and conditions under which the Executive is to be continued to be employed by the Company on and after the date hereof; and WHEREAS, the Company wishes to be assured that Executive will be available to the Company for an additional three (3) years after March 1, 1997. NOW, THEREFORE, the Company and Executive, in consideration of the mutual promises set forth herein, agree as follows: ARTICLE 1 TERM OF AGREEMENT 1.1 Commencement Date. Executive's employment with the Company under this Agreement shall commence as of March 1, 1997 ("Commencement Date") and this Agreement shall expire after a period of three (3) years from the Commencement Date, unless terminated earlier pursuant to Article 6. 1.2 Renewal. The term of this Agreement shall be automatically renewed for successive, additional three (3) year terms unless either party delivers written notice to the other at least ninety (90) days prior to the expiration date of this Agreement of an intention to terminate this Agreement or to renew it for a term of less than three (3) years but not less than (1) year. If the term of this Agreement is renewed for a term of less than three (3) years, then thereafter the term of this Agreement shall be automatically renewed for successive, additional identical terms unless either party delivers a written notice to the other at least ninety (90) days prior to a terminate date of this Agreement of an intention to terminate this Agreement or to renew it for a different term of not less than one (1) year. -1- 2 If this Agreement has not been terminated earlier pursuant to Article 6 and this Agreement is not renewed at the end of any term hereof by the Company for any reason except death, disability or retirement or other voluntary resignation of Executive, then (a) the Company shall pay to Executive all "Accrued Compensation" (as such term is defined in Section 6.1); (b) the Company shall continue to pay Executive as provided herein Executive's Base Salary over the period equal to twelve (12) months from the date of such nonrenewal of this Agreement as severance compensation; (c) the nonvested portion of the one-time contract renewal stock option grant described in Section 3.2 shall be fully vested; and (d) the Company shall pay all costs which the Company otherwise would have incurred to maintain all of Executive's health and welfare, and retirement benefits (either on the same or substantially equivalent terms and conditions) if the Executive had continued to render services to the Company for twelve (12) continuous months after the date of such nonrenewal of this Agreement. The Company shall have no further obligations to Executive other than those set forth in the preceding sentence. During such period when such Base Salary severance compensation is being paid to Executive, Executive shall not (i) engage, directly or indirectly, in providing services to any other business program or project that is competitive to a program or project being conducted by the Company or any Affiliated Company at the time of non-renewal (provided that Executive may own less than two percent (2%) of the outstanding securities of any publicly traded corporation), or (ii) solicit or attempt to solicit on behalf of himself or any other party any employee or exclusive consultant to the Company. ARTICLE 2 EMPLOYMENT DUTIES 2.1 Title/Responsibilities. Executive hereby accepts employment with the Company pursuant to the terms and conditions hereof. Executive agrees to serve the Company in the position of President and Chief Executive Officer. Executive shall report to the Board of Directors of the Company (the "Board"). Executive shall have the powers and duties commensurate with such position, including but not limited to hiring personnel necessary to carry out the responsibilities for such position as set forth in the annual business plan approved by the Board of Directors. 2.2 Full Time Attention. Executive shall devote his best efforts and his full business time and attention to the performance of the services customarily incident to such office and to such other services as the Board may reasonably request, provided that Executive may also serve on the Boards of Directors of one or more other companies with the prior written -2- 3 consent of the Board at a regularly scheduled meeting of the Board. 2.3 Other Activities. Except upon the prior written consent of the Board of Directors, Executive shall not during the period of employment engage, directly or indirectly, in any other business activity (whether or not pursued for pecuniary advantage) that is or may be competitive with, or that might place him in a competing position to that of the Company or any other corporation or entity that directly or indirectly controls, is controlled by, or is under common control with the Company (an "Affiliated Company"), provided that Executive may own less than two percent of the outstanding securities of any such publicly traded competing corporation. 2.4 Directorships. Executive will be nominated for reelection to the Company's Board of Directors throughout the term of this Agreement under the applicable provisions of the Company's Certificate of Incorporation and By-Laws. At the pleasure of the Company's shareholders, Executive agrees to serve as a Director on the Company's Board of Directors at no additional compensation. ARTICLE 3 COMPENSATION 3.1 Base Salary. Executive shall receive a Base Salary at an annual rate of Three Hundred Twenty-Eight Thousand Three Hundred Dollars ($328,300), payable every two weeks in equal installments in accordance with the Company's normal payroll practices. The Company's Board of Directors shall provide Executive with annual performance reviews, and, thereafter, Executive shall be entitled to such increase in Base Salary as the Board of Directors may from time to time establish in its sole discretion. 3.2 One-Time Renewal Bonus. The Company shall provide Executive a one-time contract renewal stock option grant in the form of an option to purchase seventy-five thousand (75,000) shares of the common stock of the Company, the maximum number of which shall be pursuant to Incentive Stock Options under the Neurocrine BioSciences, Inc. Stock Option/Stock Issuance Plan. The entire number of shares granted under such option, both Incentive and Non-Statutory, shall vest over four (4) years, with such vesting to be in accordance with the terms of the Neurocrine BioSciences, Inc. Stock Option/Stock Issuance Plan. The exercise price of this option shall be equal to the fair market value of the Company's common stock on the date of grant, which shall be the date this Agreement is approved by the Board or the Compensation Committee of the Board. -3- 4 3.3 Incentive Bonus. In addition to any other bonus Executive shall be awarded by the Company's Board of Directors, the Company shall pay Executive a bonus payment of up to seventy-five thousand dollars ($75,000) annually based upon achievement by the Company against 6 to 8 impact goals approved by the Board of Directors annually. Such goals shall be set forth in writing by the Board within ninety (90) days after the start of the Company's fiscal year and a copy shall be delivered to Executive within fifteen (15) days thereafter. The Board of Directors shall, in their sole discretion, determine whether such impact goals have been obtained. 3.4 Withholdings. All compensation and benefits payable to Executive hereunder shall be subject to all federal, state, local and other withholdings and similar taxes and payments required by applicable law. ARTICLE 4 EXPENSE ALLOWANCES AND FRINGE BENEFITS 4.1 Vacation. Executive shall be entitled to the greater of three (3) weeks of annual paid vacation or the amount of annual paid vacation to which Executive may become entitled under the terms of Company's vacation policy for employees during the term of this Agreement. 4.2 Benefits. During the term of this Agreement, the Company shall also provide Executive with the usual health insurance benefits it generally provides to its other senior management employees. As Executive becomes eligible in accordance with criteria to be adopted by the Company, the Company shall provide Executive with the right to participate in and to receive benefits from life, accident, disability, medical, pension, bonus, stock, profit-sharing and savings plans and similar benefits made available generally to employees of the Company as such plans and benefits may be adopted by the Company, provided that Executive shall during the term of this Agreement be entitled to receive at a minimum standard medical and dental benefits similar to those typically afforded to Chief Executive Officers in similar sized biotechnology companies. The amount and extent of benefits to which Executive is entitled shall be governed by the specific benefit plan as it may be amended from time to time. 4.3 Stock Loans. Certain indebtedness in the aggregate amount of $85,500, all of which is now due and payable, incurred by the Executive in connection with the purchase of securities from the Company shall be repaid in accordance with the terms and conditions of the Promissory Note between the Executive and the Company in the form attached hereto as Exhibit A. -4- 5 4.4 Housing Expense Loan. The Company agrees to loan to Executive the principal amount of $67,500 relating to certain housing expenses for a term ending March 1, 2000 at an interest rate of six percent (6%) per annum. Such principal indebtedness and all interest accrued to that date shall be forgiven ratably on each of March 1, 1998, March 1, 1999 and March 1, 2000 as long as Executive continues to provide services for the Company until the relevant date. If Executive's employment is terminated for Cause (as defined in Section 6.3 below), or as a result of death, disability, retirement or other voluntary resignation prior to March 1, 2000, the outstanding balance shall immediately be due and payable. 4.5 Business Expense Reimbursement. During the term of this Agreement, Executive shall be entitled to receive proper reimbursement for all reasonable out-of-pocket expenses incurred by him (in accordance with the policies and procedures established by the Company for its senior executive officers) in performing services hereunder. Executive agrees to furnish to the Company adequate records and other documentary evidence of such expenses for which Executive seeks reimbursement. Such expenses shall be reimbursed and accounted for under the policies and procedures established by the Company and the Audit Committee of the Board of Directors. ARTICLE 5 CONFIDENTIALITY 5.1 Proprietary Information. Executive represents and warrants that he has previously executed and delivered to the Company the Company's standard Proprietary Information and Inventions Agreement in form acceptable to the Company's counsel. 5.2 Return of Property. All documents, records, apparatus, equipment and other physical property which is furnished to or obtained by Executive in the course of his employment with the Company shall be and remain the sole property of the Company. Executive agrees that, upon the termination of his employment, he shall return all such property (whether or not it pertains to Proprietary Information as defined in the Proprietary Information and Inventions Agreement), and agrees not to make or retain copies, reproductions or summaries of any such property. -5- 6 ARTICLE 6 TERMINATION 6.1 By Death. The period of employment shall terminate automatically upon the death of Executive. In such event, the Company shall pay to Executive's beneficiaries or his estate, as the case may be, any accrued Base Salary, any bonus compensation to the extent earned, any vested deferred compensation (other than pension plan or profit-sharing plan benefits which will be paid in accordance with the applicable plan), any benefits under any plans of the Company in which Executive is a participant to the full extent of Executive's rights under such plans, any accrued vacation pay and any appropriate business expenses incurred by Executive in connection with his duties hereunder, all to the date of termination (collectively "Accrued Compensation"), but no other compensation or reimbursement of any kind, including, without limitation, severance compensation, and thereafter, the Company's obligations hereunder shall terminate. 6.2 By Disability. If Executive is prevented from properly performing his duties hereunder by reason of any physical or mental incapacity for a period of 120 consecutive days, or for 180 days in the aggregate in any 365-day period, then, to the extent permitted by law, the Company may terminate the employment of Executive at such time. In such event, the Company shall pay to Executive all Accrued Compensation, and shall continue to pay to Executive the Base Salary until such time (but not more than 90 days following termination), as Executive shall become entitled to receive disability insurance payments under the disability insurance policy maintained by the Company, but no other compensation or reimbursement of any kind, including without limitation, severance compensation, and thereafter the Company's obligations hereunder shall terminate. Nothing in this Section shall affect Executive's rights under any disability plan in which he is a participant. 6.3 By Company for Cause. The Company may terminate the Executive's employment for Cause (as defined below) without liability at any time with or without advance notice to Executive. The Company shall pay Executive all Accrued Compensation, but no other compensation or reimbursement of any kind, including without limitation, severance compensation, and thereafter the Company's obligations hereunder shall terminate. Termination shall be for "Cause" in the event of any of the following: (a) any intentional action or intentional failure to act by Executive which was performed in bad faith and to the material detriment of the Company; (b) Executive intentionally refuses or intentionally fails to act in accordance with any lawful and proper direction or order of the Board; (c) Executive willfully and habitually neglects the duties of employment; or (d) Executive is convicted of a felony crime involving moral turpitude, provided that in the event of the foregoing events is capable of being cured, 7 the Company shall provide written notice to Executive describing the nature of such event and Executive shall thereafter have ten (10) business days to cure such event. 6.4 Termination Without Cause. At any time, the Company may terminate the employment of Executive without liability other than as set forth below, for any reason not specified in Section 6.3 above, by giving thirty (30) days advance written notice to Executive. If the Company elects to terminate Executive pursuant to this Section 6.4, (a) the Company shall pay to Executive all Accrued Compensation; (b) the Company shall continue to pay to Executive as provided herein Executive's Base Salary over the period equal to twelve (12) months from the date of such termination as severance compensation; (c) if Executive's employment terminates in the second half of the Company's fiscal year, the Company shall make a lump-sum payment to Executive in an amount equal to a pro rata portion of the Executive's annual actual cash incentive bonus for Company's fiscal year preceding the year of termination based on the number of completed months of Executive's employment in the fiscal year divided by twelve (12); (d) the vesting of all outstanding stock options held by Executive shall be accelerated so that the amount of shares vested under such options shall equal that number of shares which would have been vested if the Executive had continued to render services to the Company for twelve (12) continuous months after the date of his termination of employment; and (e) the Company shall pay all costs which the Company would otherwise have incurred to maintain all of Executive's health and welfare, and retirement benefits (either on the same or substantially equivalent terms and conditions) if the Executive had continued to render services to the Company for twelve (12) continuous months after the date of his termination of employment. The Company shall have no further obligations to Executive other than those set forth in the preceding sentence. During the period when such Base Salary severance compensation is being paid to Executive, Executive shall not (i) engage, directly or indirectly, in providing services to any other business program or project that is competitive to a program or project being conducted by the Company or any Affiliated Company at the time of such employment termination (provided that Executive may own less than two percent (2%) of the outstanding securities of any publicly traded corporation), or (ii) solicit, or attempt to solicit on behalf of himself or any other party any employee or exclusive consultant of the Company. If the Company terminates this Agreement or the employment of Executive with the Company other than pursuant to Section 6.1, 6.2 or 6.3, then this Section 6.4 shall apply. 6.5 Constructive Termination. A Constructive Termination shall be deemed to be a termination of employment of Executive without cause pursuant to Section 6.4. For purposes of this Agreement, a "Constructive Termination" means that the Executive -7- 8 voluntary terminates his employment after any of the following are undertaken without Executive's express written consent: (a) the assignment to Executive of any duties or responsibilities which result in any diminution or adverse change of Executive's position, status or circumstances of employment; or any removal of Executive from or any failure to re-elect Executive to any of such positions, including, but not limited to, Executive's membership on the Board, except in connection with the termination of his employment for death, disability, retirement, fraud, misappropriation, embezzlement (or any other occurrence which constitutes "Cause" under Section 6.3) or any other voluntary termination of employment by Executive other than a Constructive Termination. (b) a reduction by the Company in Executive's annual Base Salary by greater than five percent (5%); (c) a relocation of Executive, or the Company's principal executive offices if Executive's principal office is at such offices, to a location more than forty (40) miles from the location at which Executive is then performing his duties, except for an opportunity to relocate which is accepted by Executive in writing; (d) any material breach by the Company of any provision of this Agreement; or (e) any failure by the Company to obtain the assumption of this Agreement by any successor or assign of the Company. 6.6 Termination Following Change in Control. In the event of a non-renewal of this Agreement, a termination without Cause or a Constructive Termination within eighteen (18) months following a Change in Control, Executive shall receive the same benefits package as Executive would have received upon a termination without Cause (except that the payment of Base Salary shall be made in the form of a lump sum), and in addition, the vesting of all outstanding stock options held by Executive shall be accelerated so that the options are immediately exercisable in full. 6.7 Change in Control. For purposes of this Agreement, a "Change in Control" shall have occurred if at any time during the term of Executive's employment hereunder, any of the following events shall occur: (a) The Company is merged, or consolidated, or reorganized into or with another corporation or other legal person, and as a result of such merger, consolidation or reorganization less than 50% of the combined voting power of the ten-outstanding securities of such corporation or person immediately after such transaction are held in the aggregate by the holders of voting -8- 9 securities of the Company immediately prior to such transaction; (b) The Company sells all or substantially all of its assets or any other corporation or other legal person and thereafter, less than 50% of the combined voting power of the then-outstanding voting securities of the acquiring or consolidated entity are held in the aggregate by the holders of voting securities of the Company immediately prior to such sale; (c) There is a report filed after the date of this Agreement on Schedule 13 D or Schedule 14 D-1 (or any successor schedule, form or report), each as promulgated pursuant to the Securities Exchange Act of 1934 (the "Exchange Act") disclosing that any person (as the term "person" is used in Section 13(d)(3) or Section 14(d)(2) of the Exchange Act) has become the beneficial owner (as the term "beneficial owner" is defined under Rule 13d-3 or any successor rule or regulation promulgated under the Exchange Act) representing 50% or more of the combined voting power of the then-outstanding voting securities of the Company; (d) The Company shall file a report or proxy statement with the Securities and Exchange Commission pursuant to the Exchange Act disclosing in response to item 1 of Form 8-X thereunder or Item 5(f) of Schedule 14 A thereunder (or any successor schedule, form or report or item therein) that the change in control of the Company has or may have occurred or will or may occur in the future pursuant to any then-existing contract or transaction; or (e) During any period of two consecutive years, individuals who at the beginning of any such period constitute the directors of the Company cease for any reason to constitute at least a majority thereof unless the election to the nomination for election by the Company's shareholders of each director of the Company first elected during such period was approved by a vote of at least two-thirds of the directors of the Company then still in office who were directors of the Company at the beginning of such period. 6.8 Termination by Executive. At any time, Executive may terminate his employment by giving thirty (30) days advance written notice to the Company. The Company shall pay Executive all Accrued Compensation, but no other compensation or reimbursement of any kind, including without limitation, severance compensation, and thereafter the Company's obligations hereunder shall terminate. 6.9 Mitigation. Except as otherwise specifically provided herein, Executive shall not be required to mitigate the amount of any payment provided under this Agreement by seeking other employment or self-employment, nor shall the amount of any payment provided for under this Agreement be reduced by any compensation earned by Executive as a result of employment by -9- 10 another employer or through self-employment or by retirement benefits after the date of Executive's termination of employment from the Company. 6.10 Coordination. If upon termination of employment Executive becomes entitled to rights under other plans, contracts or arrangements entered into by the Company, this Agreement shall be coordinated with such other arrangements so that Executive's rights under this Agreement are not reduced, and that any payments under this Agreement offset the same types of payments otherwise provided under such other arrangements, but do not otherwise reduce any payments or benefits under such other arrangements to which Executive becomes entitled. ARTICLE 7 GENERAL PROVISIONS 7.1 Governing Law. The validity, interpretation, construction and performance of this Agreement and the rights of the parties thereunder shall be interpreted and enforced under California law without reference to principles of conflicts of laws. The parties expressly agree that inasmuch as the Company's headquarters and principal place of business are located in California, it is appropriate that California law govern this Agreement. 7.2 Assignment; Successors; Binding Agreement. 7.2.1 Executive may not assign, pledge or encumber his interest in this Agreement or any part thereof. 7.2.2 The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company, by operation of law or by agreement in form and substance reasonably satisfactory to Executive, to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. 7.2.3 This Agreement shall inure to the benefit of and be enforceable by Executive's personal or legal representatives, executors, administrators, successors, heirs, distributee, devisees and legatees. If Executive should die while any amount is at such time payable to him hereunder, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to Executive's devisee, legatee or other designee or, if there be no such designee, to his estate. 7.3 Certain Reduction of Payments. In the event that any payment or benefit received or to be received by Executive under -10- 11 this Agreement would result in all or a portion of such payment to be subject to the excise tax on "golden parachute payments" under Section 4999 of the Internal Revenue Code of 1986, as amended (the "Code"), then Executive's payment shall be either (a) the full payment or (b) such lesser amount which would result in no portion of the payment being subject to excise tax under Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable Federal, state, and local employment taxes, income taxes, and the excise tax imposed by Section 4999 of the Code, results in the receipt by Executive on an after-tax basis, of the greatest amount of the payment notwithstanding that all or some portion of the payment may be taxable under Section 4999 of the Code. 7.4 Notice. For the purposes of this Agreement, notices and all other communications provided for in this Agreement shall be in writing and shall be deemed to have been duly given when delivered or mailed by certified or registered mail, return receipt requested, postage prepaid, addressed to the respective addresses set forth below or to such other address as either party may have furnished to the other in writing in accordance herewith, except that notice of change of address shall be effective only upon receipt. To the Company: Neurocrine Biosciences, Inc. 3050 Science Park Road San Diego, CA 92121 Attn: Chairman of Compensation Committee To Executive: Mr. Gary A. Lyons P.O. Box 25 Rancho Santa Fe, CA 92067 7.5 Modification; Waiver; Entire Agreement. No provisions of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing signed by Executive and such officer as may be specifically designated by the Board of the Company. No waiver by either party hereto at any time of any breach by the other party of, or compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or any prior or subsequent time. No agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either party which are not expressly set forth in this Agreement. This Agreement supersedes and amends and restates the Employment Agreement dated March 1, 1993 as amended and supplemented between the Company and the Executive. 7.6 Validity. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or -11- 12 enforceability of any other provision of this Agreement, which shall remain in full force and effect. 7.7 Controlling Document. Except to the extent described in Section 6.10, in case of conflict between any of the terms and conditions of this Agreement and the documents herein referred to, the terms and conditions of this Agreement shall control. 7.8 Executive Acknowledgment. Executive acknowledges (a) that he has consulted with or has had the opportunity to consult with independent counsel of his own choice concerning this Agreement, and has been advised to do so by the Company, and (b) that he has read and understands the Agreement, is fully aware of its legal effect, and has entered into it freely based on his own judgment. 7.9 Remedies. 7.9.1 Injunctive Relief. The parties agree that the services to be rendered by Executive hereunder are of a unique nature and that in the event of any breach or threatened breach of any of the covenants contained herein, the damage or imminent damage to the value and the goodwill of the Company's business will be irreparable and extremely difficult to estimate, making any remedy at law or in damages inadequate. Accordingly, the parties agree that the Company shall be entitled to injunctive relief against Executive in the event of any breach or threatened breach of any such provisions by Executive, in addition to any other relief (including damages) available to the Company under this Agreement or under law. 7.9.2 Exclusive. Both parties agree that the remedy specified in Section 7.9.1 above is not exclusive of any other remedy for the breach by Executive of the terms hereof. 7.10 Counterparts. This Agreement may be executed in one or more counterparts, all of which taken together shall constitute one and the same Agreement. 7.11 Negotiation Expenses. The Company will reimburse the Executive for fees and costs of negotiating this Agreement up to the amount of $4,000. -12- 13 7.12 Prevailing Party Expenses. In the event that any action or proceeding is commenced to enforce the provisions of this Agreement, the court adjudicating such action or proceeding shall award to the prevailing party all costs and expenses thereof, including, but not limited to, reasonable attorneys' fees, court costs, and all other related expenses. Executed by the parties as of the day and year first above written. NEUROCRINE BIOSCIENCES, INC. By: /s/ HARRY HIXSON JR. -------------------------- Its Chairman ----------------------- EXECUTIVE: /s/ GARY A. LYONS ----------------------------- Gary A. Lyons 14 PROMISSORY NOTE $85,500.00 March 1, 1997 Gary A. Lyons ("Obligor"), for value received, hereby promises to pay to the order of Neurocrine Biosciences, Inc., a Delaware corporation ("Payee" or the "Company"), at its principal office, the principal sum of Eighty-Five Thousand Five Hundred Dollars ($85,500.00) with interest thereon at the rate of six percent (6%) per annum on the unpaid balance of the principal sum. Accrued interest shall be due and payable quarterly on the last day of every March, June, September, and December. Interest not paid when due shall be added to principal and shall thereafter likewise bear interest. All principal together with all unpaid accrued interest shall be due and payable on March 31, 1999. All payments hereunder shall first be applied towards the payment of accrued and unpaid interest and then shall be applied towards outstanding principal. This Note may be prepaid, in whole or in part, at any time without premium or penalty. This Note shall be due and payable in full ninety (90) days following the voluntary termination of Obligor's employment with the Company or the termination of such employment by the Company for cause as set forth in the Employment Agreement dated as of March 1, 1997 between the Company and Obligor. In the event that Obligor fails to make payment on any date for payment hereinabove specified of all principal and interest due hereunder on such date, Obligor shall be deemed to be in default hereunder. In the event of such default, Payee may, at Payee's option and in Payee's sole discretion, fifteen (15) days after giving notice of default to Obligor, accelerate the maturity of all amounts due under this Note by giving notice of such acceleration if such default has not been cured in such fifteen (15) day period. This Note is secured by a pledge of 21,375 shares of Common Stock of the Company (the "Shares"), pursuant to the provisions of the Security Agreement dated as of the date hereof and in the form attached hereto as Schedule 1. In the event of a default hereunder, Payee in addition to its rights to foreclose on the Shares shall have full recourse to all other remedies available to it. The Company or other holder of this Note shall have full recourse against Obligor, and shall not be required to proceed against the Shares of other collateral securing this Note in the event of default. Exhibit A 15 Obligor waives presentment, demand for performance, notice of nonperformance, protest, notice of protest, and notice of dishonor. No delay on the part of Payee in exercising any right hereunder shall operate as a waiver of such right under this Note. This Note is being delivered in and shall be construed in accordance with the laws of the State of California. If the indebtedness represented by this Note or any part thereof is collected at law or in equity or in bankruptcy, receivership or other judicial proceedings, or if this Note is placed in the hands of attorneys for collection after default, Obligor agrees to pay, in addition to the principal and interest payable hereon, reasonable attorneys' fees and costs incurred by Payee. Any notice or other communication (except payment) required or permitted hereunder shall be in writing and shall be deemed to have been given upon delivery if personally delivered or upon deposit if deposited in the United States mail for mailing by certified mail, postage prepaid, and addressed as follows: If to Payee: Neurocrine Biosciences, Inc. 3050 Science Park Road San Diego, CA 92121 Attn: Chairman, Compensation Committee If to Obligor: Gary A. Lyons P.O. Box 25 Rancho Santa Fe, CA 92067 Any payment shall be deemed made upon receipt by Payee. Payee or Obligor may change their address for purposes of this paragraph by giving to the other party notice in conformance with this paragraph of such new address. OBLIGOR: /s/ GARY A. LYONS ----------------- Gary A. Lyons 16 Schedule 1 SECURITY AGREEMENT THIS SECURITY AGREEMENT, entered into as of March 1, 1997, between NEUROCRINE BIOSCIENCES, INC., a Delaware corporation (the "Company"), and GARY A. LYONS (the "Obligor"), W I T N E S S E T H: WHEREAS, the Company has loaned to the Obligor the sum of $85,500; and WHEREAS, the Obligor has executed and delivered to the Company a full-recourse promissory note dated as of March 1997 evidencing such loan (the "Note") and has agreed to pledge 21,375 shares of Common Stock of the Company (the "Shares") as security for the payment of the Note: NOW, THEREFORE, it is agreed as follows: 1. The Obligor hereby delivers to the Company one or more certificates representing the Shares, together with two Assignments Separate From Certificate signed by the Obligor. The Obligor hereby pledges and grants a security interest in the Shares, including any shares into which the Shares may be converted and all proceeds of the Shares, as security for the timely payment of all of the Obligor's obligations under the Note and for the Obligor's performance of all of its obligations under this Agreement. In the event of a default in payment of the Note, the Obligor hereby appoints the Company as his true and lawful attorney to take such action as may be necessary or appropriate to cause the Shares to be transferred into the name of the Company or any assignee of the Company and to take any other action on behalf of the Obligor permitted hereunder or under applicable law. 2. The Company agrees to hold the Shares as security for the timely payment of all of the Obligor's obligations under the Note and for the Obligor's performance of all of its obligations under this Agreement, as provided herein. At no time shall the Company dispose of or encumber the Shares, except as otherwise provided in this Agreement. 3. Subject to the rights of Obligor provided for in this Agreement, Obligor hereby irrevocably appoints the Company as Obligor's attorney-in-fact, coupled with an interest, with full authority in the place and stead of Obligor and in the name of Obligor, the Company or otherwise, from time to time in the Company's sole discretion, to take any action, execute any document, instrument or other agreement which the Company may deem necessary or advisable, in its sole discretion, to accomplish the purposes of this Agreement, including without -1- 17 limitation, to arrange for the transfer of the Pledged Shares on the books of the issuer to the name of the Company. 4. At all times while the Company is holding the Shares as security under this Agreement, the Company shall: (a) Collect any dividends that may be declared on the Shares and credit such dividends against any accrued interest or unpaid principal under the Note, as part payment; (b) Collect and hold any shares that may be issued upon conversion of the Shares; and (c) Collect and hold any other securities or other property that may be distributed with respect to the Shares. Such shares and other securities or property shall be subject to the security interest granted in Section 1 of this Agreement and shall be held by the Company under this Agreement. 5. While the Company holds the Shares as security under this Agreement, the Obligor shall have the right to vote the Shares at all meetings of the Company's shareholders; provided that the Obligor is not in default in the performance of any term, of this Agreement or in any payment due under the Note. The Company shall execute due and timely proxies in favor of Obligor to this end. In the event of such a default, the Company shall have the right to the extent permitted by law to vote and to give consents, ratifications and waivers and take any other action with respect to the Shares with the same force and effect as if the Company were the absolute and sole owner of the Shares. 6. Upon payment in full of the outstanding principal balance of the Note and all interest and other charges due under the Note, the Company shall release from pledge and redeliver to the Obligor the certificate(s) representing the Shares and the Assignment Separate From Certificate forms. If the Company has had the Shares transferred on the books of the issuer in order to perfect its security interest, the Company shall execute upon such release the necessary Assignments Separate From Certificate to transfer the Shares to Obligor. 7. In the event that the Obligor fails to perform any term of this Agreement or fails to make any payment when due under the Note, the Company shall have all of the rights and remedies of a creditor and secured party at law and in equity, including (without limitation) the rights and remedies provided under the California Uniform Commercial Code. Without limiting the foregoing, the Company may, after giving ten (10) days' prior written notice to the Obligor by certified mail at his residence or business address, sell any or all of the Shares in such -2- 18 manner and for such price as the Company may determine, including (without limitation) through a public or private sale or at any broker's board or on any securities exchange, for cash, upon credit or for future delivery. The Company is authorized at any such sale, if it deems it advisable to do so, to restrict the prospective bidders or purchasers of any of the Shares to persons who will represent and agree that they are purchasing for their own account for investment, and not with a view to the distribution or sale of any of the Shares, to restrict the prospective bidders or purchasers and the use any purchaser may make of the Shares and impose any other restriction or condition that the Company deems necessary or advisable under the federal and state securities laws. Upon any such sale the Company shall have the right to deliver, assign and transfer to the purchaser thereof the Shares so sold. Each purchaser at any such sale shall hold the Shares so sold absolute, free from any claim or right of any kind. In case of any sale of any or all of the Shares on credit or for future delivery, the Shares so sold may be retained by the Company until the selling price is paid by the purchaser thereof, but the Company shall not incur any liability in case of the failure of such purchaser to take up and pay for the Shares so sold and, in case of any such failure, such Shares may again be sold under the terms of this section. The Obligor hereby agrees that any disposition of any or all of the Shares by way of a private placement or other method which in the opinion of the Company is required or advisable under Federal and state securities laws is commercially reasonable. At any public sale, the Company may (if it is the highest bidder) purchase all or any part of the Shares at such price as the Company deems proper. Out of the proceeds of any sale, the Company may retain an amount sufficient to pay all amounts then due under the Note, together with the expenses of the sale and reasonable attorneys' fees. The Company shall pay the balance of such proceeds, if any, to the Obligor. The Obligor shall be liable for any deficiency that remains after the Company has exercised its rights under this Agreement. 8. This Agreement shall be governed by and construed in accordance with the laws of the State of California. This Agreement shall inure to the benefit of, and be binding upon, the Company and its successors and assigns and be binding upon the purchaser and the Obligor's legal representative, heirs, legatees, distributees, assigns and transferees by operation of law. This Agreement contains the entire security agreement between the Company and the Obligor. The Obligor will execute any additional agreements, assignments or documents or take any other actions reasonably required by the Company to preserve and -3- 19 perfect the security interest in the Shares granted to the Company herein and otherwise to effectuate this Agreement. IN WITNESS WHEREOF, the Company has caused this Agreement to be executed on its behalf by its duly authorized officer, and the Obligor has personally executed this Agreement. "Company" NEUROCRINE BIOSCIENCES, INC. By ---------------------------------- "Obligor" /s/ GARY A. LYONS ---------------------------------- Gary A. Lyons -4- 20 ASSIGNMENT SEPARATE FROM CERTIFICATE FOR VALUE RECEIVED, and pursuant to that certain Security Agreement dated as of March 1, 1997, Gary A. Lyons hereby sells, assigns and transfers unto _______________________________________________________________________ (name of transferee) ___________________________(_______) shares of Common Stock of Neurocrine Biosciences, Inc., a Delaware Corporation (the "Company") standing in ____________ name on the books of the Company represented by Certificate No. __________ herewith and hereby irrevocably constitutes and appoints _______________ Attorney to transfer said stock on the books of the Corporation with full power of substitution in the premises. Dated:______________ _________________________________ Gary A. Lyons 21 ASSIGNMENT SEPARATE FROM CERTIFICATE FOR VALUED RECEIVED, and pursuant to that certain Security Agreement dated as of March 1, 1997, Gary A. Lyons hereby sells, assigns and transfers unto _____________________________________________ (________) shares of Common (name of transferee) Stock of Neurocrine Biosciences, Inc., a Delaware Corporation (the "Company") standing in __________ name on the books of the Company represented by Certificate No. _____________ herewith and hereby irrevocably constitutes and appoints _____________________________ Attorney to transfer said stock on the books of the Corporation with full power of substitution in the premises. Dated: _______________________ /s/ GARY A. LYONS --------------------------------- Gary A. Lyons EX-10.2 3 EXHIBIT 10.2 1 EXHIBIT 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AGREEMENT, dated as of March 1, 1997, is made by and between NEUROCRINE BIOSCIENCES, INC., a Delaware corporation (hereinafter the "Company"), and ERROL B. DE SOUZA (hereinafter "Executive"). R E C I T A L S WHEREAS, the Company and Executive entered into an employment agreement as of July 1, 1993; WHEREAS, the Company and Executive wish to set forth in this Agreement the terms and conditions under which Executive is to be continued to be employed by the Company on and after the date hereof; and WHEREAS, the Company wishes to be assured that Executive will be available to the Company for an additional three (3) years after March 1, 1997. NOW, THEREFORE, the Company and Executive, in consideration of the mutual promises set forth herein, agree as follows: ARTICLE 1 TERM OF AGREEMENT 1.1 Commencement Date. Executive's employment with the Company under this Agreement shall commence as of March 1, 1997 ("Commencement Date") and this Agreement shall expire after a period of three (3) years from the Commencement Date, unless terminated earlier pursuant to Article 6. 1.2 Renewal. The term of this Agreement shall be automatically renewed for successive, additional three (3) year terms unless either party delivers written notice to the other at least ninety (90) days prior to the expiration date of this Agreement of an intention to terminate this Agreement or to renew it for a term of less than three (3) years but not less than (1) year. If the term of this Agreement is renewed for a term of less than three (3) years, then thereafter the term of this Agreement shall be automatically renewed for successive, additional identical terms unless either party delivers a written notice to the other at least ninety (90) days prior to a terminate date of this Agreement of an intention to terminate -1- 2 this Agreement or to renew it for a different term of not less than one (1) year. If this Agreement has not been terminated earlier pursuant to Article 6 and this Agreement is not renewed at the end of any term hereof by the Company for any reason except death, disability or retirement or other voluntary resignation of Executive, then (a) the Company shall pay to Executive all "Accrued Compensation" (as such term is defined in Section 6.1); (b) the Company shall continue to pay Executive as provided herein Executive's Base Salary over the period equal to twelve (12) months from the date of such nonrenewal of this Agreement as severance compensation; (c) the nonvested portion of the one-time contract renewal stock option grant described in Section 3.2 shall be fully vested; and (d) the Company shall pay all costs which the Company otherwise would have incurred to maintain all of Executive's health and welfare, and retirement benefits (either on the same or substantially equivalent terms and conditions) if the Executive had continued to render services to the Company for twelve (12) continuous months after the date of such nonrenewal of this Agreement. The Company shall have no further obligations to Executive other than those set forth in the preceding sentence. During such period when such Base Salary severance compensation is being paid to Executive, Executive shall not (i) engage, directly or indirectly, in providing services to any other business program or project that is competitive to a program or project being conducted by the Company or any Affiliated Company at the time of non-renewal (provided that Executive may own less than two percent (2%) of the outstanding securities of any publicly traded corporation), or (ii) solicit or attempt to solicit on behalf of himself or any other party any employee or exclusive consultant to the Company. ARTICLE 2 EMPLOYMENT DUTIES 2.1 Title/Responsibilities. Executive hereby accepts employment with the Company pursuant to the terms and conditions hereof. Executive agrees to serve the Company in the position of Executive Vice President, research and Development. Executive shall report to the President and Chief Executive Officer. Executive shall have the powers and duties commensurate with such position, including but not limited to hiring personnel necessary to carry out the responsibilities for such position as set forth in the annual business plan approved by the Board of Directors (the "Board"). 2.2 Full Time Attention. Executive shall devote his best efforts and his full business time and attention to the performance of the services customarily incident to such office and to such other services as the Board may -2- 3 reasonably request, provided that Executive may also serve on the Boards of Directors of one or more other companies with the prior written consent of the Board at a regularly scheduled meeting of the Board. 2.3 Other Activities. Except upon the prior written consent of the Board of Directors, Executive shall not during the period of employment engage, directly or indirectly, in any other business activity (whether or not pursued for pecuniary advantage) that is or may be competitive with, or that might place him in a competing position to that of the Company or any other corporation or entity that directly or indirectly controls, is controlled by, or is under common control with the Company (an "Affiliated Company"), provided that Executive may own less than two percent of the outstanding securities of any such publicly traded competing corporation. ARTICLE 3 COMPENSATION 3.1 Base Salary. Executive shall receive a Base Salary at an annual rate of Two Hundred Sixty-One Thousand Seven Hundred Sixteen Dollars ($261,716), payable every two weeks in equal installments in accordance with the Company's normal payroll practices. The Company's Board of Directors shall provide Executive with annual performance reviews, and, thereafter, Executive shall be entitled to such increase in Base Salary as the Board of Directors may from time to time establish in its sole discretion. 3.2 One-Time Renewal Bonus. The Company shall provide Executive a one-time contract renewal stock option grant in the form of an option to purchase fifty thousand (50,000) shares of the common stock of the Company, the maximum number of which shall be pursuant to Incentive Stock Options under the Neurocrine BioSciences, Inc. Stock Option/Stock Issuance Plan. The entire number of shares granted under such option, both Incentive and Non-Statutory, shall vest over four (4) years, with such vesting to be in accordance with the terms of the Neurocrine BioSciences, Inc. Stock Option/Stock Issuance Plan. The exercise price of this option shall be equal to the fair market value of the Company's common stock on the date of grant, which shall be the date this Agreement is approved by the Board or the Compensation Committee of the Board. 3.3 Incentive Bonus. In addition to any other bonus Executive shall be awarded by the Company's Board of Directors, the Company shall pay Executive a bonus payment of up to fifty thousand dollars ($50,000) annually based upon achievement by the Company against 6 to 8 impact goals approved by the Board of Directors annually. Such goals shall be set forth in writing by the Board within ninety (90) days after the start of the -3- 4 Company's fiscal year and a copy shall be delivered to Executive within fifteen (15) days thereafter. The Board of Directors shall, in their sole discretion, determine whether such impact goals have been obtained. 3.4 Withholdings. All compensation and benefits payable to Executive hereunder shall be subject to all federal, state, local and other withholdings and similar taxes and payments required by applicable law. ARTICLE 4 EXPENSE ALLOWANCES AND FRINGE BENEFITS 4.1 Vacation. Executive shall be entitled to the greater of three (3) weeks of annual paid vacation or the amount of annual paid vacation to which Executive may become entitled under the terms of Company's vacation policy for employees during the term of this Agreement. 4.2 Benefits. During the term of this Agreement, the Company shall also provide Executive with the usual health insurance benefits it generally provides to its other senior management employees. As Executive becomes eligible in accordance with criteria to be adopted by the Company, the Company shall provide Executive with the right to participate in and to receive benefits from life, accident, disability, medical, pension, bonus, stock, profit-sharing and savings plans and similar benefits made available generally to employees of the Company as such plans and benefits may be adopted by the Company, provided that Executive shall during the term of this Agreement be entitled to receive at a minimum standard medical and dental benefits similar to those typically afforded to Chief Executive Officers in similar sized biotechnology companies. The amount and extent of benefits to which Executive is entitled shall be governed by the specific benefit plan as it may be amended from time to time. 4.3 Relocation Loan. The Company has previously loaned to Executive the principal amount of $37,500 relating to certain relocation expenses. The parties agree that the terms of the loan shall be changed as of the date of this Agreement such that the loan shall have a term ending October 15, 1999 and an interest rate of six percent (6%) per annum. Executive agrees to execute a Promissory Note in the form attached hereto as Exhibit A. Such principal indebtedness and all interest accrued to that date shall be forgiven ratably on each of October 15, 1997, October 15, 1998 and October 15, 1999 as long as Executive continues to provide services for the Company until the relevant date. If Executive's employment is terminated for Cause (as defined in Section 6.3 below), or as a result of death, disability, retirement or other voluntary resignation prior to -4- 5 October 15, 1999, the outstanding balance shall immediately be due and payable. 4.4 Business Expense Reimbursement. During the term of this Agreement, Executive shall be entitled to receive proper reimbursement for all reasonable out-of-pocket expenses incurred by him (in accordance with the policies and procedures established by the Company for its senior executive officers) in performing services hereunder. Executive agrees to furnish to the Company adequate records and other documentary evidence of such expenses for which Executive seeks reimbursement. Such expenses shall be reimbursed and accounted for under the policies and procedures established by the Company and the Audit Committee of the Board of Directors. ARTICLE 5 CONFIDENTIALITY 5.1 Proprietary Information. Executive represents and warrants that he has previously executed and delivered to the Company the Company's standard Proprietary Information and Inventions Agreement in form acceptable to the Company's counsel. 5.2 Return of Property. All documents, records, apparatus, equipment and other physical property which is furnished to or obtained by Executive in the course of his employment with the Company shall be and remain the sole property of the Company. Executive agrees that, upon the termination of his employment, he shall return all such property (whether or not it pertains to Proprietary Information as defined in the Proprietary Information and Inventions Agreement), and agrees not to make or retain copies, reproductions or summaries of any such property. ARTICLE 6 TERMINATION 6.1 By Death. The period of employment shall terminate automatically upon the death of Executive. In such event, the Company shall pay to Executive's beneficiaries or his estate, as the case may be, any accrued Base Salary, any bonus compensation to the extent earned, any vested deferred compensation (other than pension plan or profit-sharing plan benefits which will be paid in accordance with the applicable plan), any benefits under any plans of the Company in which Executive is a participant to the full extent of Executive's rights under such plans, any accrued vacation pay and any appropriate business expenses -5- 6 incurred by Executive in connection with his duties hereunder, all to the date of termination (collectively "Accrued Compensation"), but no other compensation or reimbursement of any kind, including, without limitation, severance compensation, and thereafter, the Company's obligations hereunder shall terminate. 6.2 By Disability. If Executive is prevented from properly performing his duties hereunder by reason of any physical or mental incapacity for a period of 120 consecutive days, or for 180 days in the aggregate in any 365-day period, then, to the extent permitted by law, the Company may terminate the employment of Executive at such time. In such event, the Company shall pay to Executive all Accrued Compensation, and shall continue to pay to Executive the Base Salary until such time (but not more than 90 days following termination), as Executive shall become entitled to receive disability insurance payments under the disability insurance policy maintained by the Company, but no other compensation or reimbursement of any kind, including without limitation, severance compensation, and thereafter the Company's obligations hereunder shall terminate. Nothing in this Section shall affect Executive's rights under any disability plan in which he is a participant. 6.3 By Company for Cause. The Company may terminate the Executive's employment for Cause (as defined below) without liability at any time with or without advance notice to Executive. The Company shall pay Executive all Accrued Compensation, but no other compensation or reimbursement of any kind, including without limitation, severance compensation, and thereafter the Company's obligations hereunder shall terminate. Termination shall be for "Cause" in the event of the occurrence of any of the following: (a) any intentional action or intentional failure to act by Executive which was performed in bad faith and to the material detriment of the Company; (b) Executive intentionally refuses or intentionally fails to act in accordance with any lawful and proper direction or order of the Board; (c) Executive willfully and habitually neglects the duties of employment; or (d) Executive is convicted of a felony crime involving moral turpitude, provided that in the event that an of the foregoing events is capable of being cured, the Company shall provide written notice to Executive describing the nature of such event and Executive shall thereafter have ten (10) business days to cure such event. 6.4 Termination Without Cause. At any time, the Company may terminate the employment of Executive without liability other than as set forth below, for any reason not specified in Section 6.3 above, by giving thirty (30) days advance written notice to Executive. If the Company elects to terminate Executive pursuant to this Section 6.4, (a) the Company shall continue to pay to Executive all Accrued Compensation; (b) the Company shall continue to pay to Executive as provided herein Executive's Base Salary over the period equal to twelve (12) months from the date of such termination as severance compensation; (c) if 6 7 Executive's employment terminates in the second half of the Company's fiscal year, the Company shall make a lump-sum payment to Executive in an amount equal to a pro rata portion of the Executive's annual actual cash incentive bonus for Company's fiscal year preceding the year of termination based on the number of completed months of Executive's employment in the fiscal year divided by twelve (12); (d) the vesting of all outstanding stock options held by Executive shall be accelerated so that the amount of shares vested under such options shall equal that number of shares which would have been vested if the Executive had continued to render services to the Company for twelve (12) continuous months after the date of his termination of employment; and (e) the Company shall pay all costs which the Company would otherwise have incurred to maintain all of Executive's health and welfare, and retirement benefits (either on the same or substantially equivalent terms and conditions) if the Executive had continued to render services to the Company for twelve (12) continuous months after the date of his termination of employment. The Company shall have no further obligations to Executive other than those set forth in the preceding sentence. During the period when such Base Salary severance compensation is being paid to Executive, Executive shall not (i) engage directly or indirectly, in providing services to any other business program or project that is competitive to a program or project being conducted by the Company or any Affiliated Company at the time of such employment termination (provided that Executive may own less than two percent (2%) of the outstanding securities of any publicly traded corporation), or (ii) solicit, or attempt to solicit on behalf of himself or any other party any employee or exclusive consultant of the Company. If the Company terminates this Agreement or the employment of Executive with the Company other than pursuant to Section 6.1, 6.2 or 6.3, then this Section 6.4 shall apply. 6.5 Constructive Termination. A Constructive Termination shall be deemed to be a termination of employment of Executive without cause pursuant to Section 6.4. For purposes of this Agreement, a "Constructive Termination" means that the Executive voluntarily terminates his employment after any of the following are undertaken without Executive's express written consent: (a) the assignment to Executive of any duties or responsibilities which result in any diminution or adverse change of Executive's position, status or circumstances of employment; or any removal of Executive from or any failure to re-elect Executive to any of such positions, except in connection with the termination of his employment for death, disability, retirement, fraud, misappropriation, embezzlement (or any other occurrence which constitutes "Cause" under Section 6.3) or any other voluntary termination of employment by Executive other than a Constructive Termination; -7- 8 (b) a reduction by the Company in Executive's annual Base Salary by greater than five percent (5%); (c) a relocation of Executive, or the Company's principal executive offices if Executive's principal office is at such offices, to a location more than forty (40) miles from the location at which Executive is then performing his duties, except for an opportunity to relocate which is accepted by Executive in writing; (d) any material breach by the Company of any provision of this Agreement; or (e) any failure by the Company to obtain the assumption of this Agreement by any successor or assign of the Company. 6.6 Termination Following Change in Control. In the event of a non-renewal of this Agreement, a termination without Cause or a Constructive Termination within eighteen (18) months following a Change in Control, Executive shall receive the same benefits package as Executive would have received upon a termination without Cause (except that the payment of Base Salary shall be made in the form of a lump sum), and in addition, the vesting of all outstanding stock options held by Executive shall be accelerated so that the options are immediately exercisable in full. 6.7 Change in Control. For purposes of this Agreement, a "Change in Control" shall have occurred if at any time during the term of Executive's employment hereunder, any of the following events shall occur: (a) The Company is merged, or consolidated, or reorganized into or with another corporation or other legal person, and as a result of such merger, consolidation or reorganization less than 50% of the combined voting power of the then-outstanding securities of such corporation or person immediately after such transaction are held in the aggregate by the holders of voting securities of the Company immediately prior to such transaction; (b) The Company sells all or substantially all of its assets or any other corporation or other legal person and thereafter, less than 50% of the combined voting power of the then-outstanding voting securities of the acquiring or consolidated entity are held in the aggregate by the holders of voting securities of the Company immediately prior to such sale; (c) There is a report filed after the date of this Agreement on Schedule 13 D or Schedule 14 D-1 (or any successor schedule, form or report, each as promulgated pursuant to the Securities Exchange Act of 1934 (the "Exchange Act") disclosing that any person (as the term "person" is used in Section 13(d)(3) or Section 14(d)(2) of the Exchange Act) has become the -8- 9 beneficial owner (as the term "beneficial owner" is defined under Rule 13d-3 or any successor rule or regulation promulgated under the Exchange Act) representing 50% or more of the combined voting power of the then-outstanding voting securities of the Company; (d) The Company shall file a report or proxy statement with the Securities and Exchange Commission pursuant to the Exchange Act disclosing in response to item 1 of Form 8-X thereunder or Item 5(f) of Schedule 14 A thereunder (or any successor schedule, form or report or item therein) that the change in control of the Company has or may have occurred or will or may occur in the future pursuant to any then-existing contract or transaction; or (e) During any period of two consecutive years, individuals who at the beginning of any such period constitute the directors of the Company cease for any reason to constitute at least a majority thereof unless the election to the nomination for election by the Company's shareholders of each director of the Company first elected during such period was approved by a vote of at least two-thirds of the directors of the Company then still in office who were directors of the Company at the beginning of such period. 6.8 Termination by Executive. At any time, Executive may terminate his employment by giving thirty (30) days advance written notice to the Company. The Company shall pay Executive all Accrued Compensation, but no other compensation or reimbursement of any kind, including without limitation, severance compensation, and thereafter the Company's obligations hereunder shall terminate. 6.9 Mitigation. Except as otherwise specifically provided herein, Executive shall not be required to mitigate the amount of any payment provided under this Agreement by seeking other employment or self-employment, nor shall the amount of any payment provided for under this Agreement be reduced by any compensation earned by Executive as a result of employment by another employer or through self-employment or by retirement benefits after the date of Executive's termination of employment from the Company. 6.10 Coordination. If upon termination of employment Executive becomes entitled to rights under other plans, contracts or arrangements entered into by the Company, this Agreement shall be coordinated with such other arrangements so that Executive's rights under this Agreement are not reduced, and that any payments under this Agreement offset the same types of payments otherwise provided under such other arrangements, but do not otherwise reduce any payments or benefits under such other arrangements to which Executive becomes entitled. -9- 10 ARTICLE 7 GENERAL PROVISIONS 7.1 Governing Law. The validity, interpretation, construction and performance of this Agreement and the rights of the parties thereunder shall be interpreted and enforced under California law without reference to principles of conflicts of laws. The parties expressly agree that inasmuch as the Company's headquarters and principal place of business are located in California, it is appropriate that California law govern this Agreement. 7.2 Assignment; Successors; Binding Agreement. 7.2.1 Executive may not assign, pledge or encumber his interest in this Agreement or any part thereof. 7.2.2 The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company, by operation of law or by agreement in form and substance reasonably satisfactory to Executive, to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. 7.2.3 This Agreement shall inure to the benefit of and be enforceable by Executive's personal or legal representatives, executors, administrators, successors, heirs, distributee, devisees and legatees. If Executive should die while any amount is at such time payable to him hereunder, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to Executive's devisee, legates or other designee or, if there be no such designee, to his estate. 7.3 Certain Reduction of Payments. In the event that any payment or benefit received or to be received by Executive under this Agreement would result in all or a portion of such payment to be subject to the excise tax on "golden parachute payments" under Section 4999 of the Internal Revenue Code of 1986, as amended (the "Code"), then Executive's payment shall be either (a) the full payment or (b) such lesser amount which would result in no portion of the payment being subject to excise tax under Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable Federal, state, and local employment taxes, income taxes, and the excise tax imposed by Section 4999 of the Code, results in the receipt by Executive on an after-tax basis, of the greatest amount of the payment notwithstanding that all or some portion of the payment may be taxable under Section 4999 of the Code. -10- 11 7.4 Notice. For the purposes of this Agreement, notices and all other communications provided for in this Agreement shall be in writing and shall be deemed to have been duly given when delivered or mailed by certified or registered mail, return receipt requested, postage prepaid, addressed to the respective addresses set forth below or to such other address as either party may have furnished to the other in writing in accordance herewith, except that notice of change of address shall be effective only upon receipt. To the Company: Neurocrine Biosciences, Inc. 3050 Science Park Road San Diego, CA 92121 Attn: Chairman of Compensation Committee To Executive: Errol B. De Souza 4507 South Lane Del Mar, CA 92014 7.5 Modification; Waiver; Entire Agreement. No provisions of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing signed by Executive and such officer as may be specifically designated by the Board of the Company. No waiver by either party hereto at any time of any breach by the other party of, or compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or any prior or subsequent time. No agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either party which are not expressly set forth in this Agreement. This Agreement supersedes and amends and restates the Employment Agreement dated July 1, 1993 as amended and supplemented between the Company and the Executive. 7.6 Validity. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect. 7.7 Controlling Document. Except to the extent described in Section 6.10, in case of conflict between any of the terms and conditions of this Agreement and the documents herein referred to, the terms and conditions of this Agreement shall control. -11- 12 7.8 Executive Acknowledgment. Executive acknowledges (a) that he has consulted with or has had the opportunity to consult with independent counsel of his own choice concerning this Agreement, and has been advised to do so by the Company, and (b) that he has read and understands the Agreement, is fully aware of its legal effect, and has entered into it freely based on his own judgment. 7.9 Remedies. 7.9.1 Injunctive Relief. The parties agree that the services to be rendered by Executive hereunder are of a unique nature and that in the event of any breach or threatened breach of any of the covenants contained herein, the damage or imminent damage to the value and the goodwill of the Company's business will be irreparable and extremely difficult to estimate, making any remedy at law or in damages inadequate. Accordingly, the parties agree that the Company shall be entitled to injunctive relief against Executive in the event of any breach or threatened breach of any such provisions by Executive, in addition to any other relief (including damages) available to the Company under this Agreement or under law. 7.9.2 Exclusive. Both parties agree that the remedy specified in Section 7.9.1 above is not exclusive of any other remedy for the breach by Executive of the terms hereof. 7.10 Counterparts. This Agreement may be executed in one or more counterparts, all of which taken together shall constitute one and the same Agreement. 12 13 7.11 Prevailing Party Expenses. In the event that any action or proceeding is commenced to enforce the provisions of this Agreement, the court adjudicating such action or proceeding shall award to the prevailing party all costs and expenses thereof, including, but not limited to, reasonable attorneys' fees, court costs, and all other related expenses. Executed by the parties as of the day and year first above written. NEUROCRINE BIOSCIENCES, INC. By /s/ GARY LYONS -------------------------------- Its CEO ------------------------------ EXECUTIVE: /s/ ERROL B. DE SOUZA ------------------------------------- Errol B. De Souza -13- 14 EXHIBIT A PROMISSORY NOTE $37,500.00 March 1, 1997 Errol B. De Souza ("Obligor"), for value received, hereby promises to pay to the order of Neurocrine Biosciences, Inc., a Delaware corporation ("Payee" or the "Company"), at its principal office, the principal sum of Thirty-Seven Thousand Five Hundred Dollars ($37,500.00) with interest thereon at the rate of six percent (6%) per annum on the unpaid balance of the principal sum. All principal together with all unpaid accrued interest shall be due and payable on October 15, 1999. All payments hereunder shall first be applied towards the payment of accrued and unpaid interest and then shall be applied towards outstanding principal. This Note may be prepaid, in whole or in part, at any time without premium or penalty. The principal sum of this Note and all interest accrued to that date shall be forgiven ratably on each of October 15, 1997, October 15, 1998 and October 15, 1999 as long as Obligor continues to provide services for the Company until the relevant date. This Note shall be due and payable in full immediately following the termination of Obligor's employment with the Company prior to October 15, 1999 as a result of death, disability, retirement or other voluntary resignation, or for Cause as set forth in the Employment Agreement dated as of March 1, 1997 between the Company and Obligor. In the event that Obligor fails to make payment on any date for payment hereinabove specified of all principal and interest due hereunder on such date, Obligor shall be deemed to be in default hereunder. In the event of such default, Payee may, at Payee's option and in Payee's sole discretion, fifteen (15) days after giving notice of default to Obligor, accelerate the maturity of all amounts due under this Note by giving notice of such acceleration if such default has not been cured in such fifteen (15) day period. This Note currently is unsecured. However, the Company at its discretion may secure this Note with a deed of trust encumbering Obligor's principal residence. In the event of a default hereunder, Payee in addition to its rights to foreclose on such principal residence shall have full recourse to all other remedies available to it. The Company or other holder of this Note shall have full recourse against Obligor, and shall not be required to proceed against such principal residence or other collateral securing this Note in the event of default. 15 Obligor waives presentment, demand for performance, notice of nonperformance, protest, notice of protest, and notice of dishonor. No delay on the part of Payee in exercising any right hereunder shall operate as a waiver of such right under this Note. This Note is being delivered in and shall be construed in accordance with the laws of the State of California. If the indebtedness represented by this Note or any part thereof is collected at law or in equity or in bankruptcy, receivership or other judicial proceedings, or if this Note is placed in the hands of attorneys for collection after default, Obligor agrees to pay, in addition to the principal and interest payable hereon, reasonable attorneys' fees and costs incurred by Payee. Any notice or other communication (except payment) required or permitted hereunder shall be in writing and shall be deemed to have been given upon delivery if personally delivered or upon deposit if deposited in the United States mail for mailing by certified mail, postage prepaid, and addressed as follows: If to Payee: Neurocrine Biosciences, Inc. 3050 Science Park Road San Diego, CA 92121 Attn: Chairman, Compensation Committee If to Obligor: Errol B. De Souza 4507 South Lane Del Mar, CA 92014 Any payment shall be deemed made upon receipt by Payee. Payee or Obligor may change their address for purposes of this paragraph by giving to the other party notice in conformance with this paragraph of such new address. OBLIGOR: /s/ ERROL B. DE SOUZA ---------------------- Errol B. De Souza EX-10.3 4 EXHIBIT 10.3 1 EXHIBIT 10.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AGREEMENT, dated as of March 1, 1997, is made by and between NEUROCRINE BIOSCIENCE, INC., a Delaware corporation (hereinafter the "Company"), and PAUL W. HAWRAN (hereinafter "Executive"). R E C I T A L S WHEREAS, the Company and Executive entered into an employment agreement as of May 8, 1993; WHEREAS, the Company and Executive wish to set forth in this Agreement the terms and conditions under which Executive is to be continued to be employed by the Company on and after the date hereof; and WHEREAS, the Company wishes to be assured that Executive will be available to the Company for an additional three (3) years after March 1, 1997. NOW, THEREFORE, the Company and Executive, in consideration of the mutual promises set forth herein, agree as follows: ARTICLE 1 TERM OF AGREEMENT 1.1 Commencement Date. Executive's employment with the Company under this Agreement shall commence as of March 1, 1997 ("Commencement Date") and this Agreement shall expire after a period of three (3) years from the Commencement Date, unless terminated earlier pursuant to Article 6. 1.2 Renewals. The term of this Agreement shall be automatically renewed for successive, additional three (3) year terms unless either party delivers written notice to the other at least ninety (90) days prior to the expiration date of this Agreement of an intention to terminate this Agreement or to renew it for a term of less than three (3) years but not less than (1) year. If the term of this Agreement is renewed for a term of less than three (3) years, then thereafter the term of this Agreement shall be automatically renewed for successive, additional identical terms unless either party delivers a written notice to the other at least ninety (90) days prior to a terminate date of this Agreement of an intention to terminate -1- 2 this Agreement or to renew it for a different term of not less than one (1) year. If this Agreement has not been terminated earlier pursuant to Article 6 and this Agreement is not renewed at the end of any term hereof by the Company for any reason except death, disability or retirement or other voluntary resignation of Executive, then (a) the Company shall pay to Executive all "Accrued Compensation" (as such term is defined in Section 6.1); (b) the Company shall continue to pay Executive as provided herein Executive's Base Salary over the period equal to twelve (12) months from the date of such nonrenewal of this Agreement as severance compensation; (c) the nonvested portion of the one-time contract renewal stock option grant described in Section 3.2 shall be fully vested; and (d) the Company shall pay all costs which the Company otherwise would have incurred to maintain all of Executive's health and welfare, and retirement benefits (either on the same or substantially's equivalent terms and conditions) if the Executive had continued to render services to the Company for twelve (12) continuous months after the date of such nonrenewal of this Agreement. The Company shall have no further obligations to Executive other than those set forth in the preceding sentence. During such period when such Base Salary severance compensation is being paid to Executive, Executive shall not (i) engage, directly or indirectly, in providing services to any other business program or project that is competitive to a program or project being conducted by the Company or any Affiliated Company at the time of non-renewal (provided that Executive may own less than two percent (2%) of the outstanding securities of any publicly traded corporation), or (ii) solicit or attempt to solicit on behalf of himself or any other party any employee or exclusive consultant to the Company. ARTICLE 2 EMPLOYMENT DUTIES 2.1 Title/Responsibilities. Executive hereby accepts employment with the Company pursuant to the terms and conditions hereof. Executive agrees to serve the Company in the position of Senior Vice President and Chief Financial Officer. Executive shall report to the President and Chief Executive Officer. Executive shall have the powers and duties commensurate with such position, including not but limited to hiring personnel necessary to carry out the responsibilities for such position as set forth in the annual business plan approved by the Board of Directors of the Company (the "Board"). 2.2 Full Time Attention. Executive shall devote his best efforts and his full business time and attention to the performance of the services customarily incident to such office and to such other services as the President or Board may -2- 3 reasonably request, provided that Executive may also serve on the Boards of Directors of one or more other companies with the prior written consent of the Board at a regularly scheduled meeting of the Board. 2.3 Other Activities. Except upon the prior written consent of the Board of Directors, Executive shall not during the period of employment engage, directly or indirectly, in any other business activity (whether or not pursued for pecuniary advantage) that is or may be competitive with, or that might place him in a competing position to that of the Company or any other corporation or entity that directly or indirectly controls, is controlled by, or is under common control with the Company (a "Affiliated Company"), provided that Executive may own less than two percent of the outstanding securities of any such publicly traded competing corporation. ARTICLE 3 COMPENSATION 3.1 Base Salary. Executive shall receive a Base Salary at an annual rate of Two Hundred Nine Thousand Seven Hundred Forty Dollars ($209,740), payable every two weeks in equal installments in accordance with the Company's normal payroll practices. The Company's Board of Directors shall provide Executive with annual performance reviews, and, thereafter, Executive shall be entitled to such increase in Base Salary as the Board of Directors may from time to time establish in its sole discretion. 3.2 One-Time Renewal Bonus. The Company shall provide Executive a one-time contract renewal stock option grant in the form of an option to purchase fifty thousand (50,000) shares of the common stock of the Company, the maximum number of which shall be pursuant to Incentive Stock Options under the Neurocrine Biosciences, Inc. Stock Option/Stock Issuance Plan. The entire number of shares granted under such option, both Incentive and Non-Statutory, shall vest over four (4) years, with such vesting to be in accordance with the terms of the Neurocrine BioSciences, Inc. Stock Option/Stock Issuance Plan. The exercise price of this option shall be equal to the fair market value of the Company's common stock on the date of grant, which shall be the date this Agreement is approved by the Board or the Compensation Committee of the Board. 3.3 Incentive Bonus. In addition to any other bonus Executive shall be awarded by the Company's Board of Directors, the Company shall pay Executive a bonus payment of up to fifty thousand dollars ($50,000) annually based upon achievement by the Company against 6 to 8 impact goals approved by the Board of Directors annually. Such goals shall be set forth in writing by the Board within ninety (90) days after the start of the -3- 4 Company's fiscal year and a copy shall be delivered to Executive within fifteen (15) days thereafter. The Board of Directors shall, in their sole discretion, determine whether such impact goals have been obtained. 3.4 Withholdings. All compensation and benefits payable to Executive hereunder shall be subject to all federal, state local and other withholdings and similar taxes and payments required by applicable law. ARTICLE 4 EXPENSE ALLOWANCES AND FRINGE BENEFITS 4.1 Vacation. Executive shall be entitled to the greater of three (3) weeks of annual paid vacation or the amount of annual paid vacation to which Executive may become entitled under the terms of Company's vacation policy for employees during the term of this Agreement. 4.2 Benefits. During the term of this Agreement, the Company shall also provide Executive with the usual health insurance benefits its generally provides to its other senior management employees. As Executive becomes eligible in accordance with criteria to be adopted by the Company, the Company shall provide Executive with the right to participate in and to receive benefits from life, accident, disability, medical, pension, bonus, stock, profit-sharing and savings plans and similar benefits made available generally to employees of the Company as such plans and benefits may be adopted by the Company, provided that Executive shall during the term of this Agreement be entitled to receive at a minimum standard medical and dental benefits similar to those typically afforded to Chief Financial Officer in similar sized biotechnology companies. The amount and extend of benefits to which Executive is entitled shall be governed by the specific benefit plan as it may be amended from time to time. 4.3 Stock Loans. Certain indebtedness in the aggregate amount of $15,000, incurred by the Executive in connection with the purchase of securities from the Company, shall be repaid in accordance with the terms and conditions of the Promissory Note between the Executive and the Company in the form attached hereto as Exhibit A. 4.4 Relocation Loan. The Company has previously loaned to Executive the principal amount of $87,500 relating to certain relocation expenses. The parties agree that the terms of the loan shall be changed as of the date of this Agreement such that the loan shall be changed as of the date of this Agreement such that the loan shall have a term ending March 1, 2000 and an interest rate of six percent (6%) per annum. Executive agrees to execute a Promissory Note in the form attached hereto as Exhibit B. Such principal indebtedness and all interest accrued to that -4- 5 date shall be forgiven ratably on each of March 1, 1998, March 1, 1999 and March 1, 2000 as long as Executive continues to provide services for the Company until the relevant date. If Executive's employment is terminated for Cause (as defined in Section 6.3 below), or as a result of death, disability, retirement or other voluntary resignation prior to March 1, 2000, the outstanding balance shall immediately be due and payable. 4.5 Business Expense Reimbursement. During the term of this Agreement, Executive shall be entitled to receive proper reimbursement for all reasonable out-of-pocket expenses incurred by him (in accordance with the policies and procedures established by the Company for its senior executive officers) in performing services hereunder. Executive agrees to furnish to the Company adequate records and other documentary evidence of such expenses for which Executive seeks reimbursement. Such expenses shall be reimbursed and accounted for under the policies and procedures established by the Company and the Audit Committee of the Board of Directors. ARTICLE 5 CONFIDENTIALITY 5.1 Proprietary Information. Executive represents and warrants that he has previously executed and delivered to the Company the Company's standard Proprietary Information and Inventions Agreement in form acceptable to the Company's counsel. 5.2 Return of Property. All documents, records, apparatus, equipment and other physical property which is furnished to or obtained by Executive in the course of his employment with the Company shall be and remain the sole property of the Company. Executive agrees that, upon the termination of his employment, he shall return all such property (whether or not it pertains to Proprietary Information as defined in the Proprietary Information and Inventions Agreement), and agrees not to make or retain copies, reproductions or summaries of any such property. ARTICLE 6 TERMINATION 6.1 By Death. The period of employment shall terminate automatically upon the death of Executive. In such event, the Company shall pay to Executive's beneficiaries or his estate, as the case may be, any accrued Base Salary, any bonus compensation -5- 6 to the extent earned, any vested deferred compensation (other than pension plan or profit-sharing plan benefits which will be paid in accordance with the applicable plan), any benefits under any plans of the Company in which Executive is a participant to the full extent of Executive's rights under such plans, any accrued vacation pay and any appropriate business expenses incurred by Executive in connection with his duties hereunder, all to the date of termination (collectively "Accrued Compensation"), but no other compensation or reimbursement of any kind, including, without limitation, severance compensation, and thereafter, the Company's obligations hereunder shall terminate. 6.2 By Disability. If Executive is prevented from properly performing his duties hereunder by reason of any physical or mental incapacity for a period of 120 consecutive days, or for 180 days in the aggregate in any 365-day period, then, to the extent permitted by law, the Company may terminate the employment of Executive at such time. In such event, the Company shall continue to pay Executive all Accrued Compensation, and shall continue to pay to Executive the Base Salary until such time (but not more than 90 days following termination), as Executive shall become entitled to receive disability insurance payments under the disability insurance policy maintained by the Company, but no other compensation or reimbursement of any kind, including without limitation, severance compensation, and thereafter the Company's obligations hereunder shall terminate. Nothing in this Section shall affect Executive's rights under any disability plan in which he is a participant. 6.3 By Company for Cause. The Company may terminate the Executive's employment for Cause (as defined below) without liability at any time with or without advance notice to Executive. The Company shall pay Executive all Accrued Compensation, but not other compensation or reimbursement of any kind, including without limitation, severance compensation, and thereafter the Company's obligations hereunder shall terminate. Termination shall be for "Cause" in the event of the occurrence of any of the following: (a) any intentional action or intentional failure to act by Executive which was performed in bad faith and to the material detriment of the Company; (b) Executive intentionally refuses or intentionally fails to act in accordance with any lawful and proper direction or order of the Board; (c) Executive willfully and habitually neglects the duties of employment; or (d) Executive is convicted of a felony crime involving moral turpitude, provided that in the event that any of the foregoing events is capable of being cured, the Company shall provide written notice to Executive describing the nature of such event and Executive shall thereafter have ten (10) business days to cure such event. 6.4 Termination Without Cause. At any time, the Company may terminate the employment of Executive without liability other than as set forth below, for any reason not specified in Section 6.3 above, by giving thirty 930) days advance written -6- 7 notice to Executive. If the Company elects to terminate Executive pursuant to this Section 6.4, (a) the Company shall pay to Executive all Accrued Compensation; (b) the Company shall continue to pay to Executive as provided herein Executive's Base Salary over the period equal to twelve (12) months from the date of such termination as severance compensation; (c) if Executive's employment terminates in the second half of the Company's fiscal year, the Company shall make a lump-sum payment to Executive in an amount equal to a pro rate portion of the Executive's annual actual cash incentive bonus for Company's fiscal year preceding the year of termination based on the number of completed months of Executive's employment in the fiscal year divided by twelve (12); (d) the vesting of all outstanding stock options held by Executive shall be accelerated so that the amount of shares vested under such options shall equal that number of shares which would have been vested if the Executive had continued to render services to the Company for twelve (12) continuous months after the date of his termination of employment; and (e) the Company shall pay all costs which the Company would otherwise have incurred to maintain all of Executive's health and welfare, and retirement benefits (either on the same or substantially equivalent terms and conditions) if the Executive had continued to render services to the Company for twelve (12) continuous months after the date of his termination of employment. The Company shall have no further obligations to Executive other than those set forth in the preceding sentence. During the period when such Base Salary severance compensation is being paid to Executive, Executive shall not (i) engage, directly or indirectly, in providing services to any other business program or project that is competitive to a program or project being conducted by the Company or any Affiliated company at the time of such employment termination (provided that Executive may own less than two percent (2%) of the outstanding securities of any publicly traded corporation), or (ii) solicit, or attempt to solicit on behalf of himself or any other party any employee or exclusive consultant of the Company. If the Company terminates this Agreement or the employment of Executive with the Company other than Pursuant to Section 6.1, 6.2 or 6.3, then this Section 6.4 shall apply. 6.5 Constructive Termination. A Constructive Termination shall be deemed to be a termination of employment of Executive without cause pursuant to Section 6.4. For purposes of this Agreement, a "Constructive Termination" means that the Executive voluntary terminates his employment after any of the following are undertaken without Executive's express written consent: (a) the assignment to Executive of any duties or responsibilities which result in any diminution or adverse change of Executive's position, status or circumstances of employment; or any removal of Executive from or any failure to re-elect Executive to any of such positions, except in connection with the termination of his employment for death, -7- 8 disability, retirement, fraud, misappropriation, embezzlement (or any other occurrence which constitutes "Cause" under Section 6.3) or any other voluntary termination of employment by Executive other than a Constructive Termination. (b) a reduction by the Company in Executive's annual Base Salary by greater than five percent (5%); (c) a relocation of Executive, or the Company's principal executive offices if Executive's principal office is at such offices, to a location more than forty (40) miles from the location at which Executive is then performing his duties, except for an opportunity to relocate which is accepted by Executive in writing; (d) any material breach by the Company of any provision of this Agreement; or (e) any failure by the Company to obtain the assumption of this Agreement by any successor or assign of the Company. 6.6 Termination Following Change in Control. In the event of a non-renewal of this Agreement, a termination without Cause or a Constructive Termination within eighteen (18) months following a Change in Control, Executive shall receive the same benefits package as Executive would have received upon a termination without Cause (except that the payment of Base Salary shall be made in the form of a lump sum), and in addition, the vesting of all outstanding stock options held by Executive shall be accelerated so that the options are immediately exercisable in full. 6.7 Change in Control. For purposes of this Agreement, a "Change in Control" shall have occurred if at any time during the term of Executive's employment hereunder, any of the following events shall occur: (a) The Company is merged, or consolidated, or reorganized into or with another corporation or other legal person, and as a result of such merger, consolidation or reorganization less than 50% of the combined voting power of the then-outstanding securities of such corporation or person immediately after such transaction are held in the aggregate by the holders of voting securities of the Company immediately prior to such transaction; (b) The Company sells all or substantially all of its assets or any other corporation or other legal person and thereafter, less than 50% of the combined voting power of the then-outstanding voting securities of the acquiring or consolidated entity are held in the aggregate by the holders of voting securities of the Company immediately prior to such sale; -8- 9 (c) There is a report filed after the date of this Agreement on Schedule 13 D or Schedule 14 D-1 (or any successor schedule, form or report), each as promulgated pursuant to the Securities Exchange Act of 1934 (the "Exchange Act") disclosing that any person (as the term "person" is used in Section 13(d)(3) or Section 14(d)(2) of the Exchange Act) has become the beneficial owner (as the term "beneficial owner" is defined under Rule 13d-3 or any successor rule or regulation promulgated under the Exchange Act) representing 50% or more of the combined voting power of the then-outstanding voting securities of the Company; (d) The Company shall file a report or proxy statement with the Securities and Exchange Commission pursuant to the Exchange Act disclosing in response to item 1 of Form 8-X thereunder or Item 5(f) of Schedule 14 A thereunder (or any successor schedule, form or report or item therein) that the change in control of the Company has or may have occurred or will or may occur in the future pursuant to any then-existing contract or transaction; or (e) During any period of two consecutive years, individuals who at the beginning of any such period constitute the directors of the Company cease for any reason to constitute at least a majority thereof unless the election to the nomination for election by the Company's shareholders of each director of the Company first elected during such period was approved by a vote of at least two-thirds of the directors of the Company then still in office who were directors of the Company at the beginning of such period. 6.8 Termination by Executive. At any time, Executive may terminate his employment by giving thirty (30) days advance written notice to the Company, The Company shall pay Executive all Accrued Compensation, but no other compensation or reimbursement of any kind, including without limitation, severance compensation, and thereafter the Company's obligations hereunder shall terminate. 6.9 Mitigation. Except as otherwise specifically provided herein, Executive shall not be required to mitigate the amount of any payment provided under this Agreement by seeking other employment or self-employment, nor shall the amount of any payment provided for under this Agreement be reduced by any compensation earned by Executive as a result of employment by another employer or through self-employment or by retirement benefits after the date of Executive's termination of employment from the Company. 6.10 Coordination. If upon termination of employment Executive becomes entitled to rights under other plans, contracts or arrangements entered into by the Company, this Agreement shall be coordinated with such other arrangements so that Executive's rights under this Agreement are not reduced, -9- 10 and that any payments under this Agreement offset the same types of payments otherwise provided under such other arrangements, but do not otherwise reduce any payments or benefits under such other arrangements to which Executive becomes entitled. ARTICLE 7 GENERAL PROVISIONS 7.1 Governing Law. The validity, interpretation, construction and performance of this Agreement and the rights of the parties thereunder shall be interpreted and enforced under California law without reference to principles of conflicts of laws. The parties expressly agree that inasmuch as the Company's headquarters and principal place of business are located in California, it is appropriate that California law govern this Agreement. 7.2 Assignment; Successors; Binding Agreement. 7.2.1 Executive may not assign, pledge or encumber his interest in this Agreement or any part thereof. 7.2.2 The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company, by operation of law or by agreement in form and substance reasonably satisfactory to Executive, to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. 7.2.3 This Agreement shall inure to the benefit of and be enforceable by Executive's personal or legal representatives, executors, administrators, successors, heirs, distributee, devisees and legatees. If Executive should die while any amount is at such time payable to him hereunder, all such amounts unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to Executive's devisee, legates or other designee or, if there be no such designee, to his estate. 7.3 Certain Reduction of Payments. In the event that any payment or benefit received or to be received by Executive under this Agreement would result in all or a portion of such payment to be subject to the excise tax on "golden parachute payments" under Section 4999 of the Internal Revenue Code of 1986, as amended (the "Code"), then Executive's payment shall be either (a) the full payment or (b) such lesser amount which would result in no portion of the payment being subject to excise tax under Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable Federal, state, and local employment taxes, income taxes, and the excise tax imposed -10- 11 by Section 4999 of the Code, results in the receipt by Executive on an after-tax basis, of the greatest amount of the payment notwithstanding that all or some portion of the payment may be taxable under Section 4999 of the Code. 7.4 Notice. For the purposes of this Agreement, notices and all other communications provided for in this Agreement shall be in writing and shall be deemed to have been duly given when delivered or mailed by certified or registered mail, return receipt requested, postage prepaid, addressed to the respective addresses set forth below or to such other address as either party may have furnished to the other in writing in accordance herewith, except that notice of change of address shall be effective only upon receipt. To the Company: Neurocrine Biosciences, Inc. 3050 Science Park Road San Diego, CA 92121 Attn: Chairman of Compensation Committee To Executive: Mr. Paul W. Hawran P.O. Box 1162 Rancho Santa Fe, CA 92067 7.5 Modification; Waiver; Entire Agreement. No provisions of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing signed by Executive and such officer as may be specifically designated by the Board of the Company. No waiver by either party hereto at any time of any breach by the other party of, or compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or any prior or subsequent time. No agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either party which are not expressly set forth in this Agreement. This Agreement supersedes and amends and restates the Employment Agreement dated May 8, 1993 as amended and supplemented between the Company and the Executive. 7.6 Validity. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect. 7.7 Controlling Document. Except to the extent described in Section 6.10, in case of conflict between any of the terms and conditions of this Agreement and the documents herein referred to, the terms and conditions of this Agreement shall control. 11 12 7.8 Executive Acknowledgement. Executive acknowledges (a) that he has consulted with or has had the opportunity to consult with independent counsel of his own choice concerning this Agreement, and has been advised to do so by the Company, and (b) that he has read and understands the Agreement, is fully aware of its legal effect, and has entered into it freely based on his own judgment. 7.9 Remedies. 7.9.1 Injunctive Relief. The parties agree that the services to be rendered by Executive hereunder are of a unique nature and that in the event of any breach or threatened breach of any of the covenants contained herein, the damage or imminent damage to the value and the goodwill of the Company's business will be irreparable and extremely difficult to estimate, making any remedy at law or in damages inadequate. Accordingly, the parties agree that the Company shall be entitled to injunctive relief against Executive in the event of any breach or threatened breach of any such provisions by Executive, in addition to any other relief (including damages) available to the Company under this Agreement or under law. 7.9.2 Exclusive. Both parties agree that the remedy specified in Section 7.9.1 above is not exclusive of any other remedy for the breach by Executive of the terms hereof. 7.10 Counterparts. This agreement may be executed in one or more counterparts, all of which taken together shall constitute one and the same Agreement. -12- 13 7.11 Prevailing Party Expenses. In the event that any action or proceeding is commenced to enforce the provisions of this Agreement, the court adjudicating such action or proceeding shall award to the prevailing party all costs and expenses thereof, including, but not limited to, reasonable attorneys' fees, court costs, and all other related expenses. Executed by the parties as of the day and year first above written. NEUROCRINE BIOSCIENCES, INC. By /s/ GARY LYONS -------------------------------- Its CEO ---------------------------- EXECUTIVE: /s/ PAUL W. HAWRAN ----------------------------------- Paul W. Hawran -13- 14 EXHIBIT A PROMISSORY NOTE $15,000.00 March 1, 1997 - Paul W. Hawran ("Obligor"), for value received, hereby promises to pay to the order of Neurocrine Biosciences, Inc., a Delaware corporation ("Payee" or the "Company"), at its principal office, the principal sum of Fifteen Thousand Dollars ($15,000.00) with interest thereon at the rate of six percent (6%) per annum on the unpaid balance of the principal sum. Accrued interest shall be due and payable quarterly on the last day of every March, June, September, and December. Interest note paid when due shall be added to principal and shall thereafter likewise bear interest. All principal together with all unpaid accrued interest shall be due and payable on March 31, 1999. All payments hereunder shall first be applied towards the payment of accrued and unpaid interest and then shall be applied towards outstanding principal. This Note may be prepaid, in whole or in part, at any time without premium or penalty. This Note shall be due and payable in full ninety (90) days following the voluntary termination of Obligor's employment with the Company, or the termination of such employment by the Company for Cause as set forth in the Employment Agreement dated as of March 1, 1997 between the Company and Obligor. In the event that Obligor fails to make payment on any date for payment hereinabove specified of all principal and interest due hereunder on such date, Obligor shall be deemed to be in default hereunder. In the event of such default, Payee may, at Payee's option and in Payee's sole discretion, fifteen (15) days after giving notice of default to Obligor, accelerate the maturity of all amounts due under this Note by giving notice of such acceleration if such default has not been cured in such fifteen (15) day period. This Note is secured by a pledge of 3,750 shares of Common Stock of the Company (the "Shares"), pursuant to the provisions of the Security Agreement dated as of the date hereof and in the form attached hereto as Schedule 1. In the event of a default hereunder, Payee in addition to its rights to foreclose on the Shares shall have full recourse to all other remedies available to it. The Company or other holder of this Note shall have full recourse against obligor, and shall not be required to proceed against the Shares or other collateral securing this Note in the event of default. 15 Obligor waives presentment, demand for performance, notice of nonperformance, protest, notice of protest, and notice of dishonor. No delay on the part of Payee in exercising any right hereunder shall operate as a waiver of such right under this Note. This Note is being delivered in and shall be construed in accordance with the laws of the State of California. If the indebtedness represented by this Note or any part thereof is collected at law or in equity or in bankruptcy, receivership or other judicial proceedings, or if this Note is placed in the hands of attorneys for collection after default, Obligor agrees to pay, in addition to the principal and interest payable hereon, reasonable attorneys' fees and costs incurred by Payee. Any notice or other communication (except payment) required or permitted hereunder shall be in writing and shall be deemed to have been given upon delivery if personally delivered or upon deposit if deposited in the United States mail for mailing by certified mail, postage prepaid, and addressed as follows: If to Payee: Neurocrine Biosciences, Inc. 3050 Science Park Road San Diego, CA 92121 Attn: Chairman, Compensation Committee If to Obligor: Paul W. Hawran P.O. Box 1162 Rancho Santa Fe, CA 92067 Any payment shall be deemed made upon receipt by Payee. Payee or Obligor may change their address for purposes of this paragraph by giving to the other party notice in conformance with this paragraph of such new address. OBLIGOR: /s/ PAUL W. HAWRAN ----------------- Paul W. Hawran 16 Schedule 1 SECURITY AGREEMENT THIS SECURITY AGREEMENT, entered into as of March 1, 1997, between NEUROCRINE BIOSCIENCES, INC., a Delaware corporation (the "Company"), and PAUL W. HAWRAN (the "Obligor"), W I T N E S S E T H: WHEREAS, the Company has loaned to the Obligor the sum of $15,000; and WHEREAS, the Obligor has executed and delivered to the Company a full-recourse promissory note dated as of March 1, 1997 evidencing such loan (the "Note") and has agreed to pledge 3,750 shares of Common Stock of the Company (the "Shares") as security for the payment of the Note: NOW, THEREFORE, it is agreed as follows: 1. The Obligor hereby delivers to the Company one or more certificates representing the Shares, together with two Assignments Separate From Certificate signed by the Obligor. The Obligor hereby pledges and grants a security interest in the Shares, including any shares into which the Shares may be converted and all proceeds of the Shares, as security for the timely payment of all of the Obligor's obligations under the Note and for the Obligor's performance of all of its obligations under this Agreement. In the event of a default in payment of the Note, the Obligor hereby appoints the Company as his true and lawful attorney to take such action as may be necessary or appropriate to cause the Shares to be transferred into the name of the Company or any assignee of the Company and to take any other action on behalf of the Obligor permitted hereunder or under applicable law. 2. The Company agrees to hold the Shares as security for the timely payment of all of the Obligor's obligations under the Note and for the Obligor's performance of all of its obligations under this Agreement, as provided herein. At no time shall the Company dispose of or encumber the Shares, except as otherwise provided in this Agreement. 3. Subject to the rights of Obligor provided for in this Agreement, Obligor hereby irrevocably appoints the Company as Obligor's attorney-in-fact, coupled with an interest, with full authority in the place and stead of Obligor and in the name of Obligor, the Company or otherwise, from time to time in the Company's sole discretion, to take any action, execute any document, instrument or other agreement which the Company may deem necessary or advisable, in its sole discretion, to accomplish the purposes of this Agreement, including without 17 limitation, to arrange for the transfer of the Pledged Shares on the books of the issuer to the name of the Company. 4. At all times while the Company is holding the Shares as security under this Agreement, the Company shall: (a) Collect any dividends that may be declared on the Shares and credit such dividends against any accrued interest or unpaid principal under the Note, as part payment; (b) Collect and hold any shares that may be issued upon conversion of the Shares; and (c) Collect and hold any other securities or other property that may be distributed with respect to the Shares. Such shares and other securities or property shall be subject to the security interest granted in Section 1 of this Agreement and shall be held by the Company under this Agreement. 5. While the Company holds the Shares as security under this Agreement, the Obligor shall have the right to vote the Shares at all meetings of the Company's shareholders; provided that the Obligor is not in default in the performance of any term of this Agreement or in any payment due under the Note. The Company shall execute due and timely proxies in favor of Obligor to this end. In the event of such a default, the Company shall have the right to the extent permitted by law to vote and to give consents, ratifications and waivers and take any action with respect to the Shares with the same force and effect as if the Company were the absolute and sole owner of the Shares. 6. Upon payment in full of the outstanding principal balance of the Note and all interest and other charges due under the Note, the Company shall release from pledge and redeliver to the Obligor the certificate(s) representing the Shares and the Assignment Separate From Certificate forms. If the Company has had the Shares transferred on the books of the issuer in order to perfect its security interest, the Company shall execute upon such release the necessary Assignments Separate From Certificate to transfer the Shares to Obligor. 7. In the event that the Obligor fails to perform any terms of this Agreement or fails to make any payment when due under the Note, the Company shall have all of the rights and remedies of a creditor and secured party at law and in equity, including (without limitation) the rights and remedies provided under the California Uniform Commercial Code. Without limiting the foregoing, the Company may, after giving ten (10) days' prior written notice to the Obligor by certified mail at his residence or business address, sell any or all of the Shares in such 2 18 manner and for such price as the Company may determine, including (without limitation) through a public or private sale or at any broker's board or on any securities exchange, for cash, upon credit or for future delivery. The Company is authorized at any such sale, if it deems it advisable to do so, to restrict the prospective bidders or purchasers of any of the Shares to persons who will represent and agree that they are purchasing for their own account for investment, and not with a view to the distribution or sale of any of the Shares, to restrict the prospective bidders or purchasers and the use any purchaser may make of the Shares and impose any other restriction or condition that the Company deems necessary or advisable under the federal and state securities laws. Upon any such sale the Company shall have the right to deliver, assign and transfer to the purchaser thereof the Shares so sold. Each purchaser at any such sale shall hold the Shares so sold absolute, free from any claim or right of any kind. In case of any sale of any or all of the Shares on credit or for future delivery, the Shares so sold may be retained by the Company until the selling price is maid by the purchaser thereof, but the Company shall not incur any liability in case of the failure of such purchaser to take up and Day for the Shares so sold and, in case or any such failure, such Shares may again be sold under the terms of this section. The Obligor hereby agrees that any disposition of any or all of the Shares by way of a private placement or other method which in the opinion of the Company is required or advisable under Federal and state securities laws is commercially reasonable. At any public sale, the Company may (if it is the highest bidder) purchase all or any part of the Shares at such price as the Company deems proper. Out of the proceeds of any sale, the Company may retain an amount sufficient to pay all amounts then due under the Note, together with the expenses of the sale and reasonable attorneys' fees. The Company shall Day the balance of such proceeds, if any, to the Obligor. The Obligor shall be liable for any deficiency that remains after the Company has exercised its rights under this Agreement. 8. This Agreement shall be governed by and construed in accordance with the laws of the State of California. This Agreement shall inure to the benefit of, and be binding upon, the Company and its successors and assigns and be binding upon the purchaser and the Obligor's legal representative, heirs, legatees, distributees, assigns and transferees by operation of law. This Agreement contains the entire security agreement between the Company and the Obligor. The Obligor will execute any additional agreements, assignments or documents or take any other actions reasonably required by the Company to preserve and -3- 19 perfect the security interest in the Shares granted to the Company herein and otherwise to effectuate this Agreement. IN WITNESS WHEREOF, the Company has caused this Agreement to be executed on its behalf by its duly authorized officer, and the Obligor has personally executed this Agreement. "Company" NEUROCRINE BIOSCIENCES, INC. By /s/ GARY LYONS --------------------------------- "Obligor" /s/ PAUL W. HAWRAN --------------------------------- Paul W. Hawran -4- 20 ASSIGNMENT SEPARATE FROM CERTIFICATE FOR VALUE RECEIVED, and pursuant to that certain Security Agreement dated as of March 1, 1997, Paul W. Hawran hereby sells, assigns and transfers unto _______________________________________________________________________ (name of transferee) ___________________________(_______) shares of Common Stock of Neurocrine Biosciences, Inc. , a Delaware Corporation (the "Company") standing in ____________ name on the books of the Company represented by Certificate No. __________ herewith and hereby irrevocably constitutes and appoints _______________ Attorney to transfer said stock on the books of the Corporation with full power of substitution in the premises. Dated:______________ /s/ PAUL W. HAWRAN ------------------ Paul W. Hawran 21 EXHIBIT B PROMISSORY NOTE $87,500.00 March 1, 1997 Paul W. Hawran ("Obligor"), for value received, hereby promises to pay to the order of Neurocrine Biosciences, Inc., a Delaware corporation ("Payee" or the "Company"), at its principal office, the principal sum of Eighty-Seven Thousand Five Hundred Dollars ($87,500.00) with interest thereon at the rate of six percent (6%) per annum on the unpaid balance of the principal sum. All principal together with all unpaid accrued interest shall be due and payable on March 1, 2000. All payments hereunder shall first be applied towards the payment of accrued and unpaid interest and then shall be applied towards outstanding principal. This Note may be prepaid, in whole or in part, at any time without premium or penalty. The principal sum of this Note and all interest accrued to that date shall be forgiven ratably on each of March 1, 1998, March 1, 1999 and March 1, 2000 as long as Obligor continues to provide services for the Company until the relevant date. This Note shall be due and payable in full immediately following the termination of Obligor's employment with the Company prior to March 1, 2000 as a result of death, disability, retirement or other voluntary resignation, or for Cause as set forth in the Employment Agreement dated as of March 1, 1997 between the Company and Obligor. In the event that Obligor fails to make payment on any date for payment hereinabove specified of all principal and interest due hereunder on such date, Obligor shall be deemed to be in default hereunder. In the event of such default, Payee may, at Payee's option and in Payee's sole discretion, fifteen (15) days after giving notice of default to Obligor, accelerate the maturity of all amounts due under this Note by giving notice of such acceleration if such default has not been cured in such fifteen (15) day period. This Note currently is unsecured. However, the Company at its discretion may secure this Note with a deed of trust encumbering Obligor's principal residence. In the event of a default hereunder, Payee in addition to its rights to foreclose on such principal residence shall have full recourse to all other remedies available to it. The Company or other holder of this Note shall have full recourse against Obligor, and shall not be required to proceed against such principal residence or other collateral securing this Note in the event of default. 22 Obligor waives presentment, demand for performance, notice of nonperformance, protest, notice of protest, and notice of dishonor. No delay on the part of Payee in exercising any right hereunder shall operate as a waiver of such right under this Note. This Note is being delivered in and shall be construed in accordance with the laws of the State of California. If the indebtedness represented by this Note or any part thereof is collected at law or in equity or in bankruptcy, receivership or other judicial proceedings, or if this Note is placed in the hands of attorneys for collection after default, Obligor agrees to pay, in addition to the principal and interest payable hereon, reasonable attorneys' fees and costs incurred by Payee. Any notice or other communication (except payment) required or permitted hereunder shall be in writing and shall be deemed to have been given upon delivery if personally delivered or upon deposit if deposited in the United States mail for mailing by certified mail, postage prepaid, and addressed as follows: If to Payee: Neurocrine Biosciences, Inc. 3050 Science Park Road San Diego, CA 92121 Attn: Chairman, Compensation Committee If to Obligor: Paul W. Hawran P.O. Box 1162 Rancho Santa Fe, CA 92067 Any payment shall be deemed made upon receipt by Payee. Payee or Obligor may change their address for purposes of this paragraph by giving to the other party notice in conformance with this paragraph of such new address. OBLIGOR: /s/ PAUL W. HAWRAN ------------------ Paul W. Hawran EX-27.4 5 FINANCIAL DATA SCHEDULE
5 3-MOS DEC-31-1997 APR-01-1997 JUN-30-1997 22,945,469 40,631,271 7,653,719 0 0 72,558,104 5,516,054 0 84,020,525 5,496,019 0 0 0 83,151,069 0 84,020,525 0 4,801,194 0 5,784,152 (239,512) 0 40,785 125,806 22,393 0 0 0 0 103,413 .01 .01
-----END PRIVACY-ENHANCED MESSAGE-----